1	Of	of	IN	_	2	case	_	_
2	note	note	NN	_	24	ppmod	_	_
3	,	,	,	_	24	p	_	_
4	however	however	RB	_	24	adv	_	_
5	,	,	,	_	24	p	_	_
6	GALNT2	galnt0	NN	_	7	com	_	_
7	drug1	drug0	NN	_	24	dep	_	_
8	(	-lrb-	-LRB-	_	7	p	_	_
9	previously	previously	RB	_	10	adv	_	_
10	associated	associate	VBN	_	7	acl	_	_
11	with	with	IN	_	15	case	_	_
12	high-density	high-density	JJ	_	14	attr	_	_
13	lipoprotein	lipoprotein	NN	_	14	com	_	_
14	cholesterol	cholesterol	NN	_	15	com	_	_
15	levels	level	NNS	_	10	ppmod	_	_
16	in	in	IN	_	17	case	_	_
17	EA	ea	NN	_	15	ppmod	_	_
18	)	-rrb-	-RRB-	_	7	p	_	_
19	had	have	VBD	_	24	lv	_	_
20	multiple	multiple	JJ	_	24	attr	_	_
21	potentially	potentially	RB	_	22	adv	_	_
22	novel	novel	JJ	_	24	attr	_	_
23	PheWAS	phewas	NN	_	24	com	_	_
24	associations	association	NNS	_	0	root	_	_
25	,	,	,	_	24	p	_	_
26	with	with	IN	_	29	case	_	_
27	hypertension	hypertension	NN	_	29	attr	_	_
28	related	related	JJ	_	29	attr	_	_
29	phenotypes	phenotype	NNS	_	24	ppmod	_	_
30	in	in	IN	_	31	case	_	_
31	AA	aa	NN	_	29	ppmod	_	_
32	and	and	CC	_	29	cc	_	_
33	with	with	IN	_	36	case	_	_
34	serum	serum	NN	_	36	com	_	_
35	calcium	calcium	NN	_	36	com	_	_
36	levels	level	NNS	_	29	conj	_	_
37	and	and	CC	_	36	cc	_	_
38	drug2	drug0	NN	_	39	com	_	_
39	phenotypes	phenotype	NNS	_	36	conj	_	_
40	in	in	IN	_	41	case	_	_
41	EA	ea	NN	_	36	ppmod	_	_
42	.	.	.	_	24	p	_	_

1	The	the	DT	_	2	det	_	_
2	majority	majority	NN	_	8	dep	_	_
3	of	of	IN	_	7	case	_	_
4	the	the	DT	_	7	det	_	_
5	potentially	potentially	RB	_	6	adv	_	_
6	novel	novel	JJ	_	7	attr	_	_
7	results	result	NNS	_	2	ppmod	_	_
8	were	be	VBD	_	34	advcl	_	_
9	for	for	IN	_	12	case	_	_
10	single	single	JJ	_	12	attr	_	_
11	PheWAS	phewas	NN	_	12	com	_	_
12	phenotype-classes	phenotype-classes	NNS	_	8	ppmod	_	_
13	,	,	,	_	34	p	_	_
14	for	for	IN	_	15	case	_	_
15	example	example	NN	_	34	ppmod	_	_
16	,	,	,	_	34	p	_	_
17	for	for	IN	_	19	case	_	_
18	CDKN2A/B	cdkn0a/b	NN	_	19	com	_	_
19	drug1	drug0	NN	_	34	ppmod	_	_
20	(	-lrb-	-LRB-	_	19	p	_	_
21	previously	previously	RB	_	22	adv	_	_
22	associated	associate	VBN	_	19	acl	_	_
23	with	with	IN	_	26	case	_	_
24	type	type	NN	_	26	attr	_	_
25	2	0	CD	_	26	num	_	_
26	drug2	drug0	NN	_	22	ppmod	_	_
27	in	in	IN	_	28	case	_	_
28	EA	ea	NN	_	26	ppmod	_	_
29	)	-rrb-	-RRB-	_	19	p	_	_
30	a	a	DT	_	32	det	_	_
31	PheWAS	phewas	JJ	_	32	attr	_	_
32	association	association	NN	_	34	dep	_	_
33	was	be	VBD	_	34	aux	_	_
34	identified	identify	VBN	_	0	root	_	_
35	for	for	IN	_	37	case	_	_
36	hemoglobin	hemoglobin	NN	_	37	com	_	_
37	levels	level	NNS	_	34	ppmod	_	_
38	in	in	IN	_	39	case	_	_
39	AA	aa	NN	_	37	ppmod	_	_
40	.	.	.	_	34	p	_	_

1	However	however	RB	_	26	adv	_	_
2	,	,	,	_	26	p	_	_
3	the	the	DT	_	4	det	_	_
4	effect	effect	NN	_	26	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	:	:	:	_	6	p	_	_
8	C>G	c>g	NNP	_	6	attr	_	_
9	in	in	IN	_	11	case	_	_
10	INK4	ink0	NN	_	11	com	_	_
11	locus	locus	NN	_	6	ppmod	_	_
12	in	in	IN	_	15	case	_	_
13	familial	familial	JJ	_	15	attr	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	patients	patient	NNS	_	11	ppmod	_	_
16	and	and	CC	_	11	cc	_	_
17	on	on	IN	_	19	case	_	_
18	lipid	lipid	NN	_	19	com	_	_
19	profile	profile	NN	_	11	conj	_	_
20	of	of	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	patients	patient	NNS	_	19	ppmod	_	_
23	has	have	VBZ	_	26	aux	_	_
24	not	not	RB	_	26	neg	_	_
25	been	be	VBN	_	26	aux	_	_
26	studied	study	VBN	_	0	root	_	_
27	in	in	IN	_	28	case	_	_
28	Pakistan	pakistan	NN	_	26	ppmod	_	_
29	.	.	.	_	26	p	_	_

1	An	an	DT	_	3	det	_	_
2	epistatic	epistatic	JJ	_	3	attr	_	_
3	interaction	interaction	NN	_	20	dep	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	OR	or	CC	_	10	cc	_	_
10	1.56	0	CD	_	7	num	_	_
11	,	,	,	_	10	p	_	_
12	p=1.19	p=0	NN	_	13	com	_	_
13	*	*	NN	_	10	appo	_	_
14	10	0	CD	_	13	num	_	_
15	(	-lrb-	-LRB-	_	13	p	_	_
16	-2	0	CD	_	13	num	_	_
17	)	-rrb-	-RRB-	_	13	p	_	_
18	)	-rrb-	-RRB-	_	10	p	_	_
19	was	be	VBD	_	20	aux	_	_
20	found	find	VBN	_	0	root	_	_
21	especially	especially	RB	_	23	adv	_	_
22	in	in	IN	_	23	case	_	_
23	presence	presence	NN	_	20	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	drug3	drug0	NN	_	26	com	_	_
26	disease	disease	NN	_	23	ppmod	_	_
27	(	-lrb-	-LRB-	_	31	p	_	_
28	OR=2.15	or=0	CD	_	31	num	_	_
29	,	,	,	_	31	p	_	_
30	p=3.12	p=0	CD	_	31	num	_	_
31	*	*	NN	_	26	prn	_	_
32	10	0	CD	_	31	num	_	_
33	(	-lrb-	-LRB-	_	31	p	_	_
34	-4	0	CD	_	31	num	_	_
35	)	-rrb-	-RRB-	_	31	p	_	_
36	)	-rrb-	-RRB-	_	31	p	_	_
37	.	.	.	_	20	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	longitudinal	longitudinal	JJ	_	4	attr	_	_
4	study	study	NN	_	29	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	11	0	CD	_	7	num	_	_
7	years	year	NNS	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	follow-up	follow-up	NN	_	7	ppmod	_	_
10	on	on	IN	_	11	case	_	_
11	survival	survival	NN	_	4	ppmod	_	_
12	in	in	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	oldest-old	oldest-old	JJ	_	15	attr	_	_
15	Danes	danes	NN	_	11	ppmod	_	_
16	,	,	,	_	29	p	_	_
17	only	only	RB	_	18	adv	_	_
18	one	#crd#	CD	_	19	num	_	_
19	SNP	snp	NN	_	29	dep	_	_
20	,	,	,	_	19	p	_	_
21	drug1	drug0	NN	_	19	appo	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	IL6	il0	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	,	,	,	_	19	p	_	_
26	was	be	VBD	_	29	aux	_	_
27	borderline	borderline	NN	_	28	advnp	_	_
28	significantly	significantly	RB	_	29	adv	_	_
29	associated	associate	VBN	_	0	root	_	_
30	with	with	IN	_	31	case	_	_
31	drug2	drug0	NN	_	29	ppmod	_	_
32	from	from	IN	_	33	case	_	_
33	age	age	NN	_	31	ppmod	_	_
34	92	0	CD	_	33	num	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	P-corrected=0.064	p-corrected=0	NNP	_	29	prn	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	.	.	.	_	29	p	_	_

1	Haplotypes	haplotype	NNS	_	10	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	or	or	CC	_	3	cc	_	_
7	drug3	drug0	NN	_	3	conj	_	_
8	and	and	CC	_	7	cc	_	_
9	drug4	drug0	NN	_	7	conj	_	_
10	revealed	reveal	VBD	_	0	root	_	_
11	an	an	DT	_	12	det	_	_
12	association	association	NN	_	10	obj	_	_
13	with	with	IN	_	15	case	_	_
14	drug5	drug0	NN	_	15	com	_	_
15	cancer	cancer	NN	_	12	ppmod	_	_
16	which	which	WDT	_	17	dep	_	_
17	was	be	VBD	_	15	relcl	_	_
18	significantly	significantly	RB	_	19	adv	_	_
19	stronger	strong	JJR	_	17	dep	_	_
20	in	in	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	homozygous	homozygous	JJ	_	23	attr	_	_
23	carriers	carrier	NNS	_	17	ppmod	_	_
24	.	.	.	_	10	p	_	_

1	The	the	DT	_	4	det	_	_
2	nonsynonymous	nonsynonymous	JJ	_	4	attr	_	_
3	OPRM1	oprm0	NN	_	4	com	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	might	might	MD	_	6	modal	_	_
6	be	be	VB	_	0	root	_	_
7	a	a	DT	_	9	det	_	_
8	risk	risk	NN	_	9	com	_	_
9	factor	factor	NN	_	6	obj	_	_
10	for	for	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	opioids	opioids	NN	_	11	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	heroin	heroin	NN	_	13	conj	_	_
16	in	in	IN	_	19	case	_	_
17	an	an	DT	_	19	det	_	_
18	Asian	asian	JJ	_	19	attr	_	_
19	population	population	NN	_	6	ppmod	_	_
20	.	.	.	_	6	p	_	_

1	No	no	DT	_	2	det	_	_
2	association	association	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	found	find	VBN	_	0	root	_	_
5	between	between	IN	_	7	case	_	_
6	drug2	drug0	JJ	_	7	attr	_	_
7	phenotypes	phenotype	NNS	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	incidence	incidence	NN	_	7	prn	_	_
10	,	,	,	_	9	p	_	_
11	intensity	intensity	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	duration	duration	NN	_	9	conj	_	_
15	)	-rrb-	-RRB-	_	9	p	_	_
16	and	and	CC	_	7	cc	_	_
17	different	different	JJ	_	19	attr	_	_
18	drug1	drug0	NN	_	19	com	_	_
19	genotypes	genotype	NNS	_	7	conj	_	_
20	.	.	.	_	4	p	_	_

1	Results	result	NNS	_	0	root	_	_
2	revealed	reveal	VBD	_	1	acl	_	_
3	an	an	DT	_	4	det	_	_
4	association	association	NN	_	2	obj	_	_
5	between	between	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	cocaine	cocaine	NN	_	6	conj	_	_
9	and	and	CC	_	8	cc	_	_
10	heroin	heroin	NN	_	11	com	_	_
11	drug2	drug0	NN	_	8	conj	_	_
12	in	in	IN	_	14	case	_	_
13	European	european	NNP	_	14	com	_	_
14	Americans	americans	NNP	_	2	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	p=0.02	p=0	NN	_	14	prn	_	_
17	;	;	:	_	16	p	_	_
18	95	0	CD	_	20	num	_	_
19	%	%	NN	_	18	meta	_	_
20	C.I.	c.i.	NNP	_	16	comp	_	_
21	0.47	0	CD	_	20	num	_	_
22	-LSB-0.24-0.92	-lsb-0	CD	_	20	num	_	_
23	]	-rsb-	-RRB-	_	20	p	_	_
24	)	-rrb-	-RRB-	_	16	p	_	_

1	The	the	DT	_	3	det	_	_
2	118G	0g	NN	_	3	com	_	_
3	allele	allele	NN	_	4	dep	_	_
4	conferred	confer	VBD	_	0	root	_	_
5	5.3-fold	0-fold	RB	_	7	adv	_	_
6	increased	increase	VBN	_	7	attr	_	_
7	odds	odds	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	/	/	:	_	9	p	_	_
11	drug3	drug0	NN	_	9	appo	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	p<0.05	p<0	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	,	,	,	_	4	p	_	_
16	while	while	IN	_	23	mark	_	_
17	the	the	DT	_	20	det	_	_
18	drug1	drug0	NN	_	20	attr	_	_
19	variant	variant	JJ	_	20	attr	_	_
20	allele	allele	NN	_	23	dep	_	_
21	was	be	VBD	_	23	aux	_	_
22	not	not	RB	_	23	neg	_	_
23	associated	associate	VBN	_	4	comp	_	_
24	with	with	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	/	/	:	_	4	p	_	_
27	drug5	drug0	NN	_	4	dep	_	_

1	In	in	IN	_	4	case	_	_
2	this	this	DT	_	4	det	_	_
3	meta	meta	NN	_	4	com	_	_
4	analysis	analysis	NN	_	11	ppmod	_	_
5	,	,	,	_	11	p	_	_
6	we	we	PRP	_	11	dep	_	_
7	assessed	assess	VBD	_	11	aux	_	_
8	10	0	CD	_	10	num	_	_
9	case-control	case-control	JJ	_	10	attr	_	_
10	studies	study	NNS	_	11	obj	_	_
11	included	include	VBD	_	0	root	_	_
12	7,067	0	CD	_	13	num	_	_
13	cases	case	NNS	_	11	obj	_	_
14	and	and	CC	_	13	cc	_	_
15	9,374	0	CD	_	16	num	_	_
16	controls	control	NNS	_	13	conj	_	_
17	of	of	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	association	association	NN	_	13	ppmod	_	_
20	between	between	IN	_	24	case	_	_
21	CYP1B1	cyp0b0	NN	_	24	attr	_	_
22	SNPs	snp	NNS	_	24	attr	_	_
23	of	of	IN	_	24	case	_	_
24	Leu432Val	leu0val	NN	_	19	ppmod	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	drug1	drug0	NN	_	24	prn	_	_
27	,	,	,	_	26	p	_	_
28	432C>G	0c>g	NN	_	26	appo	_	_
29	)	-rrb-	-RRB-	_	26	p	_	_
30	,	,	,	_	24	p	_	_
31	Asn453Ser	asn0ser	NNP	_	24	conj	_	_
32	(	-lrb-	-LRB-	_	35	p	_	_
33	drug2	drug0	NNP	_	35	attr	_	_
34	,	,	,	_	35	p	_	_
35	453A>G	0a>g	NNP	_	31	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	,	,	,	_	31	p	_	_
38	Ala119Ser	ala0ser	NNP	_	31	appo	_	_
39	(	-lrb-	-LRB-	_	40	p	_	_
40	drug3	drug0	NNP	_	38	prn	_	_
41	,	,	,	_	40	p	_	_
42	119G>T	0g>t	CD	_	40	appo	_	_
43	)	-rrb-	-RRB-	_	40	p	_	_
44	,	,	,	_	31	p	_	_
45	Arg48Gly	arg0gly	NNP	_	31	appo	_	_
46	(	-lrb-	-LRB-	_	47	p	_	_
47	drug4	drug0	CD	_	31	num	_	_
48	,	,	,	_	47	p	_	_
49	48C>G	0c>g	NN	_	47	appo	_	_
50	)	-rrb-	-RRB-	_	47	p	_	_
51	and	and	CC	_	31	cc	_	_
52	the	the	DT	_	53	det	_	_
53	risk	risk	NN	_	24	conj	_	_
54	of	of	IN	_	55	case	_	_
55	drug5	drug0	NN	_	53	ppmod	_	_
56	.	.	.	_	11	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	our	our	PRP$	_	6	poss	_	_
5	human	human	JJ	_	6	attr	_	_
6	study	study	NN	_	14	ppmod	_	_
7	,	,	,	_	14	p	_	_
8	the	the	DT	_	12	det	_	_
9	A118G	a0g	NN	_	12	com	_	_
10	singlenucleotide	singlenucleotide	NN	_	12	com	_	_
11	polymorphism	polymorphism	NN	_	12	com	_	_
12	drug1	drug0	NN	_	14	dep	_	_
13	was	be	VBD	_	14	aux	_	_
14	associated	associate	VBN	_	1	acl	_	_
15	with	with	IN	_	19	case	_	_
16	drug2	drug0	NN	_	19	com	_	_
17	virus	virus	NN	_	19	com	_	_
18	disease	disease	NN	_	19	com	_	_
19	severity	severity	NN	_	14	ppmod	_	_
20	(	-lrb-	-LRB-	_	23	p	_	_
21	p	p	NN	_	23	attr	_	_
22	=	=	JJ	_	23	attr	_	_
23	0.015	0	NN	_	19	num	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	.	.	.	_	1	p	_	_

1	Compared	compare	VBN	_	3	adv	_	_
2	to	to	TO	_	3	aux	_	_
3	controls	control	NNS	_	13	ppmod	_	_
4	,	,	,	_	13	p	_	_
5	drug3	drug0	NN	_	6	com	_	_
6	patients	patient	NNS	_	13	dep	_	_
7	(	-lrb-	-LRB-	_	6	p	_	_
8	with	with	IN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	without	without	IN	_	11	case	_	_
11	drug4	drug0	NN	_	8	conj	_	_
12	)	-rrb-	-RRB-	_	6	p	_	_
13	showed	show	VBD	_	0	root	_	_
14	significantly	significantly	RB	_	15	adv	_	_
15	increased	increase	VBN	_	16	attr	_	_
16	frequency	frequency	NN	_	13	obj	_	_
17	of	of	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	DBH	dbh	NN	_	16	ppmod	_	_
20	(	-lrb-	-LRB-	_	23	p	_	_
21	drug1	drug0	NN	_	23	dep	_	_
22	:	:	:	_	23	p	_	_
23	OR	or	NN	_	19	prn	_	_
24	1.73	0	CD	_	23	num	_	_
25	;	;	:	_	23	p	_	_
26	CI	ci	NN	_	23	appo	_	_
27	1.15-2.59	0	CD	_	26	num	_	_
28	;	;	:	_	23	p	_	_
29	P=0.008	p=0	CD	_	23	appo	_	_
30	)	-rrb-	-RRB-	_	23	p	_	_
31	and	and	CC	_	19	cc	_	_
32	the	the	DT	_	35	det	_	_
33	OPRM1	oprm0	NN	_	35	com	_	_
34	risk	risk	NN	_	35	com	_	_
35	genotypes	genotype	NNS	_	19	conj	_	_
36	(	-lrb-	-LRB-	_	39	p	_	_
37	drug2	drug0	NN	_	39	dep	_	_
38	:	:	:	_	39	p	_	_
39	OR	or	NN	_	35	prn	_	_
40	1.71	0	CD	_	39	num	_	_
41	;	;	:	_	39	p	_	_
42	CI	ci	NN	_	39	appo	_	_
43	1.17-2.50	0	CD	_	42	num	_	_
44	;	;	:	_	39	p	_	_
45	P=0.006	p=0	CD	_	39	appo	_	_
46	)	-rrb-	-RRB-	_	39	p	_	_
47	.	.	.	_	13	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	present	present	JJ	_	4	attr	_	_
4	study	study	NN	_	6	ppmod	_	_
5	we	we	PRP	_	6	dep	_	_
6	investigated	investigate	VBD	_	0	root	_	_
7	whether	whether	IN	_	12	mark	_	_
8	the	the	DT	_	10	det	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	SNP	snp	NN	_	12	dep	_	_
11	could	could	MD	_	12	modal	_	_
12	predict	predict	VB	_	6	comp	_	_
13	clinical	clinical	JJ	_	14	attr	_	_
14	outcome	outcome	NN	_	12	obj	_	_
15	regarding	regard	VBG	_	16	adv	_	_
16	progression	progression	NN	_	14	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	disability	disability	NN	_	18	conj	_	_
21	in	in	IN	_	22	case	_	_
22	patients	patient	NNS	_	16	ppmod	_	_
23	with	with	IN	_	25	case	_	_
24	low	low	JJ	_	25	attr	_	_
25	drug3	drug0	NN	_	22	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	drug4	drug0	NN	_	25	conj	_	_
28	after	after	IN	_	30	case	_	_
29	drug5	drug0	NN	_	30	com	_	_
30	herniation	herniation	NN	_	25	ppmod	_	_
31	.	.	.	_	6	p	_	_

1	Earlier	early	JJR	_	2	attr	_	_
2	studies	study	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	that	that	IN	_	22	mark	_	_
6	the	the	DT	_	9	det	_	_
7	single	single	JJ	_	9	attr	_	_
8	nucleotide	nucleotide	NN	_	9	com	_	_
9	polymorphism	polymorphism	NN	_	22	dep	_	_
10	drug1	drug0	JJ	_	9	attr	_	_
11	in	in	IN	_	20	case	_	_
12	the	the	DT	_	20	det	_	_
13	opioid	opioid	NN	_	20	attr	_	_
14	receptor	receptor	NN	_	20	attr	_	_
15	mu	mu	NN	_	20	attr	_	_
16	1	0	CD	_	20	num	_	_
17	(	-lrb-	-LRB-	_	20	p	_	_
18	OPRM1	oprm0	NN	_	20	attr	_	_
19	)	-rrb-	-RRB-	_	20	p	_	_
20	gene	gene	NN	_	10	ppmod	_	_
21	may	may	MD	_	22	modal	_	_
22	affect	affect	VB	_	4	comp	_	_
23	drug2	drug0	NN	_	22	obj	_	_
24	.	.	.	_	4	p	_	_

1	Individuals	individual	NNS	_	3	dep	_	_
2	were	be	VBD	_	3	aux	_	_
3	genotyped	genotyped	VBN	_	0	root	_	_
4	for	for	IN	_	6	case	_	_
5	PCSK9	pcsk0	NN	_	6	com	_	_
6	R46L	r0l	NN	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug1	drug0	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	,	,	,	_	6	p	_	_
11	ABCG8	abcg0	NN	_	12	com	_	_
12	D19H	d0h	NN	_	6	conj	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug2	drug0	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	,	,	,	_	12	p	_	_
17	and	and	CC	_	12	cc	_	_
18	APOE	apoe	NN	_	19	com	_	_
19	R112C	r0c	NNP	_	6	conj	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	drug3	drug0	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	and	and	CC	_	19	cc	_	_
24	R158C	r0c	NN	_	26	com	_	_
25	drug4	drug0	NN	_	26	com	_	_
26	polymorphisms	polymorphism	NNS	_	19	conj	_	_
27	,	,	,	_	3	p	_	_
28	all	all	DT	_	32	dep	_	_
29	of	of	IN	_	30	case	_	_
30	which	which	WDT	_	28	ppmod	_	_
31	are	be	VBP	_	32	aux	_	_
32	associated	associate	VBN	_	3	advcl	_	_
33	with	with	IN	_	34	case	_	_
34	drug5	drug0	NN	_	32	ppmod	_	_

1	Male	male	JJ	_	2	attr	_	_
2	children	child	NNS	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	alcoholics	alcoholic	NNS	_	2	ppmod	_	_
5	were	be	VBD	_	0	root	_	_
6	less	less	RBR	_	7	adv	_	_
7	likely	likely	JJ	_	5	dep	_	_
8	to	to	TO	_	9	aux	_	_
9	be	be	VB	_	5	comp	_	_
10	carriers	carrier	NNS	_	9	obj	_	_
11	of	of	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	G	g	NN	_	14	com	_	_
14	allele	allele	NN	_	10	ppmod	_	_
15	in	in	IN	_	19	case	_	_
16	single	single	JJ	_	18	attr	_	_
17	nucleotide	nucleotide	NN	_	18	com	_	_
18	polymorphism	polymorphism	NN	_	19	com	_	_
19	A118G	a0g	NN	_	14	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	drug1	drug0	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	,	,	,	_	5	p	_	_
24	and	and	CC	_	5	cc	_	_
25	those	those	DT	_	33	dep	_	_
26	who	who	WP	_	27	dep	_	_
27	were	be	VBD	_	25	relcl	_	_
28	homozygous	homozygous	JJ	_	27	dep	_	_
29	for	for	IN	_	32	case	_	_
30	the	the	DT	_	32	det	_	_
31	A	a	NN	_	32	com	_	_
32	allele	allele	NN	_	28	ppmod	_	_
33	were	be	VBD	_	5	conj	_	_
34	more	more	RBR	_	35	adv	_	_
35	likely	likely	JJ	_	33	dep	_	_
36	to	to	TO	_	37	aux	_	_
37	affiliate	affiliate	VB	_	33	comp	_	_
38	with	with	IN	_	40	case	_	_
39	alcohol	alcohol	NN	_	40	com	_	_
40	use	use	NN	_	37	ppmod	_	_
41	promoting	promote	VBG	_	37	comp	_	_
42	peers	peer	NNS	_	41	obj	_	_
43	who	who	WP	_	44	dep	_	_
44	increased	increase	VBD	_	42	relcl	_	_
45	the	the	DT	_	46	det	_	_
46	risk	risk	NN	_	44	obj	_	_
47	for	for	IN	_	49	case	_	_
48	drug2	drug0	NN	_	49	com	_	_
49	symptoms	symptom	NNS	_	46	ppmod	_	_
50	at	at	IN	_	52	case	_	_
51	all	all	DT	_	52	det	_	_
52	ages	age	NNS	_	44	ppmod	_	_
53	.	.	.	_	33	p	_	_

1	The	the	DT	_	5	det	_	_
2	COMT	comt	NN	_	5	com	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	gene	gene	NN	_	5	com	_	_
5	polymorphism	polymorphism	NN	_	8	dep	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	investigated	investigate	VBN	_	0	root	_	_
9	as	as	IN	_	12	case	_	_
10	a	a	DT	_	12	det	_	_
11	susceptibility	susceptibility	NN	_	12	com	_	_
12	factor	factor	NN	_	8	ppmod	_	_
13	for	for	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	8	p	_	_

1	No	no	DT	_	4	det	_	_
2	statistically	statistically	RB	_	3	adv	_	_
3	significant	significant	JJ	_	4	attr	_	_
4	results	result	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	found	find	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	meta-analysis	meta-analysis	NN	_	6	ppmod	_	_
9	but	but	CC	_	6	cc	_	_
10	one	#crd#	CD	_	11	num	_	_
11	study	study	NN	_	12	dep	_	_
12	reported	report	VBD	_	6	conj	_	_
13	that	that	IN	_	18	mark	_	_
14	the	the	DT	_	16	det	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	allele	allele	NN	_	18	dep	_	_
17	was	be	VBD	_	18	aux	_	_
18	associated	associate	VBN	_	12	comp	_	_
19	with	with	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	6	p	_	_

1	The	the	DT	_	4	det	_	_
2	COMT	comt	NN	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	polymorphism	polymorphism	NN	_	7	dep	_	_
5	was	be	VBD	_	7	aux	_	_
6	also	also	RB	_	7	adv	_	_
7	found	find	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	modulate	modulate	VB	_	7	comp	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	in	in	IN	_	13	case	_	_
12	normal	normal	JJ	_	13	attr	_	_
13	people	people	NN	_	9	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	.	.	.	_	7	p	_	_

1	Whites	white	NNS	_	17	dep	_	_
2	with	with	IN	_	4	case	_	_
3	allele	allele	NN	_	4	com	_	_
4	G	g	NN	_	1	ppmod	_	_
5	of	of	IN	_	11	case	_	_
6	the	the	DT	_	11	det	_	_
7	functional	functional	JJ	_	11	attr	_	_
8	polymorphism	polymorphism	NN	_	11	com	_	_
9	118A	0a	NN	_	11	com	_	_
10	>	>	NN	_	11	com	_	_
11	G	g	NN	_	4	ppmod	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	reference	reference	NN	_	15	com	_	_
14	sequence	sequence	NN	_	15	com	_	_
15	drug1	drug0	NN	_	11	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	showed	show	VBD	_	40	advcl	_	_
18	a	a	DT	_	20	det	_	_
19	smaller	small	JJR	_	20	attr	_	_
20	decrease	decrease	NN	_	17	obj	_	_
21	in	in	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	;	;	:	_	40	p	_	_
24	those	those	DT	_	40	dep	_	_
25	bearing	bear	VBG	_	24	acl	_	_
26	minor	minor	JJ	_	27	attr	_	_
27	alleles	allele	NNS	_	25	obj	_	_
28	IVS1	ivs0	NN	_	27	appo	_	_
29	+	+	CC	_	28	cc	_	_
30	1050A	0a	NN	_	28	conj	_	_
31	,	,	,	_	27	p	_	_
32	IVS1	ivs0	NN	_	27	conj	_	_
33	+	+	CC	_	32	cc	_	_
34	14123A	0a	NN	_	32	conj	_	_
35	,	,	,	_	32	p	_	_
36	and	and	CC	_	32	cc	_	_
37	IVS2	ivs0	NN	_	27	conj	_	_
38	+	+	CC	_	37	cc	_	_
39	31A	0a	NN	_	37	conj	_	_
40	showed	show	VBD	_	0	root	_	_
41	a	a	DT	_	43	det	_	_
42	larger	large	JJR	_	43	attr	_	_
43	decrease	decrease	NN	_	40	obj	_	_
44	in	in	IN	_	45	case	_	_
45	drug3	drug0	NN	_	43	ppmod	_	_
46	over	over	IN	_	48	case	_	_
47	interval	interval	NN	_	48	com	_	_
48	X	x	NN	_	40	ppmod	_	_
49	(	-lrb-	-LRB-	_	53	p	_	_
50	0.01	0	CD	_	53	num	_	_
51	<	<	NN	_	53	com	_	_
52	P	p	NN	_	53	com	_	_
53	<	<	NN	_	48	prn	_	_
54	.05	0	CD	_	53	num	_	_
55	)	-rrb-	-RRB-	_	53	p	_	_

1	Conflicting	conflict	VBG	_	2	attr	_	_
2	results	result	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	role	role	NN	_	4	ppmod	_	_
8	of	of	IN	_	16	case	_	_
9	the	the	DT	_	16	det	_	_
10	mu-opioid	mu-opioid	JJ	_	11	attr	_	_
11	receptor	receptor	NN	_	16	attr	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	OPRM1	oprm0	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	polymorphism	polymorphism	NN	_	16	com	_	_
16	A118G	a0g	NN	_	7	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	Asn40Asp	asn0asp	NN	_	16	prn	_	_
19	,	,	,	_	18	p	_	_
20	drug1	drug0	NN	_	18	appo	_	_
21	)	-rrb-	-RRB-	_	18	p	_	_
22	in	in	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	development	development	NN	_	7	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	4	p	_	_

1	drug3	drug0	NN	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	more	more	RBR	_	4	adv	_	_
4	sensitive	sensitive	JJ	_	2	dep	_	_
5	to	to	TO	_	7	aux	_	_
6	experimental	experimental	JJ	_	7	attr	_	_
7	pain	pain	NN	_	4	ppmod	_	_
8	than	than	IN	_	10	case	_	_
9	healthy	healthy	JJ	_	10	attr	_	_
10	volunteers	volunteer	NNS	_	4	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	,	,	,	_	10	p	_	_
13	in	in	IN	_	14	case	_	_
14	particular	particular	JJ	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug4	drug0	NN	_	17	com	_	_
17	individuals	individual	NNS	_	10	conj	_	_
18	with	with	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	met/met	met/met	NN	_	21	com	_	_
21	genotype	genotype	NN	_	17	ppmod	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	drug1	drug0	NN	_	24	com	_	_
24	SNP	snp	NN	_	21	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	or	or	CC	_	17	cc	_	_
27	the	the	DT	_	29	det	_	_
28	HPS-APS	hps-aps	JJ	_	29	attr	_	_
29	haplotypes	haplotype	NNS	_	17	conj	_	_
30	showing	show	VBG	_	17	acl	_	_
31	higher	high	JJR	_	33	attr	_	_
32	drug5	drug0	NN	_	33	com	_	_
33	stimuli	stimulus	NNS	_	30	obj	_	_
34	than	than	IN	_	35	case	_	_
35	patients	patient	NNS	_	4	ppmod	_	_
36	carrying	carry	VBG	_	35	acl	_	_
37	the	the	DT	_	39	det	_	_
38	LPS	lps	NN	_	39	com	_	_
39	haplotype	haplotype	NN	_	36	obj	_	_
40	or	or	CC	_	39	cc	_	_
41	val	val	NN	_	42	com	_	_
42	alleles	allele	NNS	_	39	conj	_	_
43	(	-lrb-	-LRB-	_	45	p	_	_
44	drug2	drug0	CD	_	45	num	_	_
45	NP	np	NN	_	42	prn	_	_
46	)	-rrb-	-RRB-	_	45	p	_	_
47	.	.	.	_	2	p	_	_

1	According	accord	VBG	_	4	adv	_	_
2	with	with	IN	_	4	case	_	_
3	previous	previous	JJ	_	4	attr	_	_
4	research	research	NN	_	8	ppmod	_	_
5	,	,	,	_	8	p	_	_
6	our	our	PRP$	_	7	poss	_	_
7	findings	finding	NNS	_	8	dep	_	_
8	revealed	reveal	VBD	_	0	root	_	_
9	that	that	IN	_	20	mark	_	_
10	haplotypes	haplotype	NNS	_	20	dep	_	_
11	of	of	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	COMT	comt	NN	_	15	com	_	_
14	geneand	geneand	NN	_	15	com	_	_
15	genotypes	genotype	NNS	_	10	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	drug1	drug0	NN	_	19	com	_	_
19	polymorphism	polymorphism	NN	_	15	ppmod	_	_
20	play	play	VBP	_	8	comp	_	_
21	a	a	DT	_	23	det	_	_
22	key	key	JJ	_	23	attr	_	_
23	role	role	NN	_	20	obj	_	_
24	on	on	IN	_	26	case	_	_
25	pain	pain	NN	_	26	com	_	_
26	sensitivity	sensitivity	NN	_	20	ppmod	_	_
27	in	in	IN	_	28	case	_	_
28	drug2	drug0	NN	_	20	ppmod	_	_
29	.	.	.	_	8	p	_	_

1	we	we	PRP	_	6	dep	_	_
2	assessed	assess	VBD	_	6	aux	_	_
3	10	0	CD	_	5	num	_	_
4	case-control	case-control	JJ	_	5	attr	_	_
5	studies	study	NNS	_	6	obj	_	_
6	included	include	VBD	_	0	root	_	_
7	7,067	0	CD	_	8	num	_	_
8	cases	case	NNS	_	6	obj	_	_
9	and	and	CC	_	8	cc	_	_
10	9,374	0	CD	_	11	num	_	_
11	controls	control	NNS	_	8	conj	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	association	association	NN	_	8	ppmod	_	_
15	between	between	IN	_	17	case	_	_
16	CYP1B1	cyp0b0	NN	_	17	com	_	_
17	SNPs	snp	NNS	_	14	ppmod	_	_
18	of	of	IN	_	25	case	_	_
19	Leu432Val	leu0val	NN	_	25	attr	_	_
20	drug1	drug0	NN	_	25	attr	_	_
21	Asn453Ser	asn0ser	NNP	_	25	attr	_	_
22	drug2	drug0	NNP	_	25	attr	_	_
23	,	,	,	_	25	p	_	_
24	Ala119Ser	ala0ser	NNP	_	25	com	_	_
25	drug3	drug0	NNP	_	17	ppmod	_	_
26	,	,	,	_	25	p	_	_
27	drug4	drug0	NN	_	25	attr	_	_
28	nd	nd	JJ	_	25	attr	_	_
29	the	the	DT	_	30	det	_	_
30	risk	risk	NN	_	28	advnp	_	_
31	of	of	IN	_	32	case	_	_
32	drug5	drug0	NN	_	30	ppmod	_	_
33	.	.	.	_	6	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	there	there	EX	_	6	dep	_	_
6	is	be	VBZ	_	3	comp	_	_
7	no	no	DT	_	9	det	_	_
8	direct	direct	JJ	_	9	attr	_	_
9	effect	effect	NN	_	6	obj	_	_
10	of	of	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	genotype	genotype	NN	_	9	ppmod	_	_
13	on	on	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	risk	risk	NN	_	9	ppmod	_	_
16	for	for	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	among	among	IN	_	21	case	_	_
19	active	active	JJ	_	21	attr	_	_
20	heroin	heroin	NN	_	21	com	_	_
21	users	user	NNS	_	15	ppmod	_	_
22	.	.	.	_	3	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	aimed	aim	VBD	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	investigate	investigate	VB	_	3	comp	_	_
6	associations	association	NNS	_	5	obj	_	_
7	between	between	IN	_	9	case	_	_
8	subjective	subjective	JJ	_	9	attr	_	_
9	response	response	NN	_	6	ppmod	_	_
10	to	to	TO	_	11	aux	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	6	cc	_	_
13	genetic	genetic	JJ	_	14	attr	_	_
14	polymorphisms	polymorphism	NNS	_	6	conj	_	_
15	and	and	CC	_	14	cc	_	_
16	haplotypes	haplotype	NNS	_	14	conj	_	_
17	in	in	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	u-opioid	u-opioid	JJ	_	20	attr	_	_
20	receptor	receptor	NN	_	14	ppmod	_	_
21	including	include	VBG	_	25	adv	_	_
22	the	the	DT	_	25	det	_	_
23	exonic	exonic	JJ	_	25	attr	_	_
24	variant	variant	NN	_	25	com	_	_
25	drug1	drug0	NN	_	20	ppmod	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	Asp40Asn	asp0asn	NN	_	25	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	study	study	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	focused	focus	VBN	_	0	root	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	relationship	relationship	NN	_	4	ppmod	_	_
8	between	between	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	functional	functional	JJ	_	12	attr	_	_
11	A118G	a0g	NN	_	12	com	_	_
12	polymorphism	polymorphism	NN	_	7	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	OPRM1	oprm0	NN	_	16	com	_	_
16	gene	gene	NN	_	12	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug1	drug0	NN	_	12	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	and	and	CC	_	12	cc	_	_
21	drug2	drug0	NN	_	12	conj	_	_
22	in	in	IN	_	23	case	_	_
23	groups	group	NNS	_	21	ppmod	_	_
24	of	of	IN	_	27	case	_	_
25	130	0	CD	_	27	num	_	_
26	male	male	JJ	_	27	attr	_	_
27	patients	patient	NNS	_	23	ppmod	_	_
28	and	and	CC	_	27	cc	_	_
29	452	0	CD	_	31	num	_	_
30	male	male	JJ	_	31	attr	_	_
31	controls	control	NNS	_	27	conj	_	_
32	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	7	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	present	present	JJ	_	6	attr	_	_
6	study	study	NN	_	2	ppmod	_	_
7	reveal	reveal	VBP	_	0	root	_	_
8	that	that	IN	_	14	mark	_	_
9	the	the	DT	_	12	det	_	_
10	drug1	drug0	NN	_	12	com	_	_
11	gene	gene	NN	_	12	com	_	_
12	polymorphism	polymorphism	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	associated	associate	VBN	_	7	comp	_	_
15	with	with	IN	_	19	case	_	_
16	a	a	DT	_	19	det	_	_
17	better	good	JJR	_	19	attr	_	_
18	glucose	glucose	NN	_	19	com	_	_
19	tolerance	tolerance	NN	_	14	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	improved	improved	JJ	_	22	attr	_	_
22	IS	be	VBZ	_	19	conj	_	_
23	,	,	,	_	19	p	_	_
24	both	both	DT	_	27	dep	_	_
25	of	of	IN	_	26	case	_	_
26	which	which	WDT	_	24	ppmod	_	_
27	suggest	suggest	VBP	_	19	relcl	_	_
28	a	a	DT	_	31	det	_	_
29	potential	potential	JJ	_	31	attr	_	_
30	protective	protective	JJ	_	31	attr	_	_
31	effect	effect	NN	_	27	obj	_	_
32	of	of	IN	_	34	case	_	_
33	this	this	DT	_	34	det	_	_
34	variant	variant	NN	_	31	ppmod	_	_
35	on	on	IN	_	37	case	_	_
36	drug2	drug0	NN	_	37	com	_	_
37	risk	risk	NN	_	31	ppmod	_	_
38	.	.	.	_	7	p	_	_
39	.	.	.	_	7	p	_	_

1	Moreover	moreover	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	we	we	PRP	_	4	dep	_	_
4	found	find	VBD	_	0	root	_	_
5	that	that	IN	_	9	mark	_	_
6	the	the	DT	_	8	det	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	allele	allele	NN	_	9	dep	_	_
9	was	be	VBD	_	4	comp	_	_
10	a	a	DT	_	13	det	_	_
11	dose-response	dose-response	JJ	_	13	attr	_	_
12	protective	protective	JJ	_	13	attr	_	_
13	factor	factor	NN	_	9	obj	_	_
14	for	for	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	9	cc	_	_
17	the	the	DT	_	19	det	_	_
18	epsilon3	epsilon0	NN	_	19	com	_	_
19	allele	allele	NN	_	20	dep	_	_
20	exerted	exert	VBD	_	9	conj	_	_
21	a	a	DT	_	25	det	_	_
22	weaker	weak	JJR	_	25	attr	_	_
23	dose-response	dose-response	JJ	_	25	attr	_	_
24	protective	protective	JJ	_	25	attr	_	_
25	effect	effect	NN	_	20	obj	_	_
26	for	for	IN	_	27	case	_	_
27	risk	risk	NN	_	25	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	AD	ad	NN	_	27	ppmod	_	_
30	compared	compare	VBN	_	32	adv	_	_
31	with	with	IN	_	32	case	_	_
32	epsilon2	epsilon0	NN	_	20	ppmod	_	_
33	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	was	be	VBD	_	5	aux	_	_
3	not	not	RB	_	5	neg	_	_
4	significantly	significantly	RB	_	5	adv	_	_
5	associated	associate	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	our	our	PRP$	_	10	poss	_	_
10	sample	sample	NN	_	7	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	OBJECTIVE	objective	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Previous	previous	JJ	_	4	attr	_	_
4	studies	study	NNS	_	6	dep	_	_
5	have	have	VBP	_	6	aux	_	_
6	investigated	investigate	VBN	_	1	acl	_	_
7	the	the	DT	_	8	det	_	_
8	role	role	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	CTLA-4	ctla-0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	and	and	CC	_	10	cc	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	factor-alpha	factor-alpha	NN	_	10	conj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	TNF-a	tnf-a	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	in	in	IN	_	21	case	_	_
21	carcinogenesis	carcinogenesis	NN	_	8	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	osteosarcoma	osteosarcoma	NN	_	21	ppmod	_	_
24	,	,	,	_	6	p	_	_
25	but	but	CC	_	6	cc	_	_
26	their	their	PRP$	_	27	poss	_	_
27	results	result	NNS	_	28	dep	_	_
28	were	be	VBD	_	6	conj	_	_
29	inconsistent	inconsistent	JJ	_	28	dep	_	_
30	.	.	.	_	1	p	_	_

1	Pooled	pooled	JJ	_	2	attr	_	_
2	results	result	NNS	_	0	root	_	_
3	showed	show	VBD	_	2	acl	_	_
4	that	that	IN	_	10	mark	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	polymorphism	polymorphism	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	CTLA-4	ctla-0	NN	_	6	ppmod	_	_
9	was	be	VBD	_	10	aux	_	_
10	associated	associate	VBN	_	3	comp	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	3	p	_	_

1	No	no	DT	_	3	det	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	associations	association	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	found	find	VBN	_	0	root	_	_
6	between	between	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	polymorphism	polymorphism	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	CTLA-4	ctla-0	NN	_	8	ppmod	_	_
11	or	or	CC	_	8	cc	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	polymorphism	polymorphism	NN	_	8	conj	_	_
14	of	of	IN	_	15	case	_	_
15	TNF-a	tnf-a	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug3	drug0	NN	_	18	com	_	_
18	risk	risk	NN	_	15	conj	_	_
19	.	.	.	_	5	p	_	_

1	The	the	DT	_	4	det	_	_
2	COMT	comt	NN	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	genotype	genotype	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	associated	associate	VBN	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	higher	high	JJR	_	9	attr	_	_
9	drug2	drug0	NNS	_	6	ppmod	_	_
10	on	on	IN	_	15	case	_	_
11	the	the	DT	_	15	det	_	_
12	BIS-11	bis-0	NN	_	15	com	_	_
13	second-order	second-order	NN	_	15	com	_	_
14	factor	factor	NN	_	15	com	_	_
15	Non-planning	non-planning	NN	_	9	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	total	total	JJ	_	4	attr	_	_
4	population	population	NN	_	27	ppmod	_	_
5	,	,	,	_	27	p	_	_
6	inheritance	inheritance	NN	_	27	dep	_	_
7	of	of	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	IL1R2	il0r0	NN	_	11	com	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	AA	aum	NNS	_	6	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	AA	aa	NN	_	11	appo	_	_
15	,	,	,	_	14	p	_	_
16	TNF	tnf	NN	_	17	com	_	_
17	drug3	drug0	NN	_	14	conj	_	_
18	GA	ga	NN	_	17	attr	_	_
19	+	+	CC	_	17	cc	_	_
20	AA	aa	NN	_	17	conj	_	_
21	,	,	,	_	17	p	_	_
22	and	and	CC	_	17	cc	_	_
23	TNF	tnf	NN	_	25	com	_	_
24	rs673	rs0	NN	_	25	com	_	_
25	GA	ga	NN	_	14	conj	_	_
26	genotypesmodestly	genotypesmodestly	RB	_	27	adv	_	_
27	increased	increase	VBD	_	0	root	_	_
28	drug4	drug0	NN	_	29	com	_	_
29	risk	risk	NN	_	27	obj	_	_
30	by	by	IN	_	31	case	_	_
31	1.45	0	NN	_	27	ppmod	_	_
32	to	to	TO	_	33	aux	_	_
33	11.7-fold	0-fold	NN	_	27	ppmod	_	_
34	relative	relative	JJ	_	33	attr	_	_
35	to	to	TO	_	38	aux	_	_
36	the	the	DT	_	38	det	_	_
37	referent	referent	NN	_	38	com	_	_
38	genotype	genotype	NN	_	34	ppmod	_	_
39	.	.	.	_	27	p	_	_

1	Among	among	IN	_	3	case	_	_
2	U.S.	u.s.	NN	_	3	com	_	_
3	men	man	NNS	_	19	ppmod	_	_
4	,	,	,	_	19	p	_	_
5	age-adjusted	age-adjusted	JJ	_	12	attr	_	_
6	dominant	dominant	JJ	_	12	attr	_	_
7	,	,	,	_	6	p	_	_
8	recessive	recessive	JJ	_	6	conj	_	_
9	and	and	CC	_	8	cc	_	_
10	additive	additive	JJ	_	6	conj	_	_
11	genetic	genetic	JJ	_	12	attr	_	_
12	models	model	NNS	_	19	dep	_	_
13	for	for	IN	_	17	case	_	_
14	the	the	DT	_	17	det	_	_
15	IL1R2	il0r0	NN	_	17	com	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	locus	locus	NN	_	12	ppmod	_	_
18	were	be	VBD	_	19	aux	_	_
19	linked	link	VBN	_	0	root	_	_
20	to	to	TO	_	22	aux	_	_
21	an	an	DT	_	22	det	_	_
22	increase	increase	NN	_	19	ppmod	_	_
23	in	in	IN	_	25	case	_	_
24	drug2	drug0	NN	_	25	com	_	_
25	susceptibility	susceptibility	NN	_	22	ppmod	_	_
26	.	.	.	_	19	p	_	_

1	As	as	IN	_	4	case	_	_
2	for	for	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	polymorphism	polymorphism	NN	_	9	ppmod	_	_
5	,	,	,	_	9	p	_	_
6	the	the	DT	_	8	det	_	_
7	heterogeneous	heterogeneous	JJ	_	8	attr	_	_
8	genotype	genotype	NN	_	9	dep	_	_
9	showed	show	VBD	_	0	root	_	_
10	a	a	DT	_	12	det	_	_
11	decreased	decrease	VBN	_	12	attr	_	_
12	risk	risk	NN	_	9	obj	_	_
13	for	for	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	compared	compare	VBN	_	20	adv	_	_
16	with	with	IN	_	20	case	_	_
17	the	the	DT	_	20	det	_	_
18	common	common	JJ	_	20	attr	_	_
19	homogenous	homogenous	NN	_	20	com	_	_
20	genotype	genotype	NN	_	9	ppmod	_	_
21	in	in	IN	_	24	case	_	_
22	a	a	DT	_	24	det	_	_
23	fixed-effect	fixed-effect	JJ	_	24	attr	_	_
24	model	model	NN	_	20	ppmod	_	_
25	in	in	IN	_	27	case	_	_
26	Asian	asian	JJ	_	27	attr	_	_
27	population	population	NN	_	20	ppmod	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	Met/Val	met/val	NNP	_	27	prn	_	_
30	vs	vs	CC	_	29	cc	_	_
31	.	.	.	_	9	p	_	_

1	In	in	IN	_	4	mark	_	_
2	order	order	NN	_	4	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	study	study	VB	_	0	root	_	_
5	specific	specific	JJ	_	6	attr	_	_
6	features	feature	NNS	_	4	obj	_	_
7	of	of	IN	_	11	case	_	_
8	remitting	remitting	JJ	_	10	attr	_	_
9	multiple	multiple	JJ	_	10	attr	_	_
10	sclerosis	sclerosis	NN	_	11	com	_	_
11	patients	patient	NNS	_	6	ppmod	_	_
12	with	with	IN	_	14	case	_	_
13	different	different	JJ	_	14	attr	_	_
14	genotypes	genotype	NNS	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	polymorphic	polymorphic	JJ	_	17	attr	_	_
17	loci	locus	NNS	_	14	ppmod	_	_
18	rs1800629	rs0	NN	_	20	com	_	_
19	gene	gene	NN	_	20	com	_	_
20	TNFa	tnfa	NN	_	17	appo	_	_
21	,	,	,	_	20	p	_	_
22	drug1	drug0	NN	_	24	com	_	_
23	gene	gene	NN	_	24	com	_	_
24	CD40	cd0	NN	_	20	appo	_	_
25	,	,	,	_	20	p	_	_
26	drug2	drug0	NN	_	28	com	_	_
27	gene	gene	NN	_	28	com	_	_
28	KIF1B	kif0b	NN	_	20	appo	_	_
29	,	,	,	_	20	p	_	_
30	drug3	drug0	NN	_	32	com	_	_
31	IL-18	il-0	NN	_	32	com	_	_
32	gene	gene	NN	_	20	appo	_	_
33	,	,	,	_	20	p	_	_
34	conducted	conduct	VBN	_	20	acl	_	_
35	clinical	clinical	JJ	_	38	attr	_	_
36	and	and	CC	_	35	cc	_	_
37	electrophysiological	electrophysiological	JJ	_	35	conj	_	_
38	examination	examination	NN	_	34	obj	_	_
39	of	of	IN	_	41	case	_	_
40	149	0	CD	_	41	num	_	_
41	patients	patient	NNS	_	38	ppmod	_	_
42	with	with	IN	_	43	case	_	_
43	drug4	drug0	NN	_	41	ppmod	_	_
44	.	.	.	_	4	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	determined	determine	VBN	_	0	root	_	_
4	4	0	CD	_	8	num	_	_
5	frequent	frequent	JJ	_	8	attr	_	_
6	nonsynonymous	nonsynonymous	JJ	_	8	attr	_	_
7	gene	gene	NN	_	8	com	_	_
8	polymorphisms	polymorphism	NNS	_	3	obj	_	_
9	of	of	IN	_	10	case	_	_
10	CYP1B1	cyp0b0	NN	_	8	ppmod	_	_
11	in	in	IN	_	16	case	_	_
12	the	the	DT	_	16	det	_	_
13	human	human	JJ	_	16	attr	_	_
14	drug5	drug0	NN	_	16	com	_	_
15	cell	cell	NN	_	16	com	_	_
16	lines	line	NNS	_	10	ppmod	_	_
17	panels	panel	NNS	_	8	appo	_	_
18	of	of	IN	_	23	case	_	_
19	the	the	DT	_	23	det	_	_
20	National	national	JJ	_	23	attr	_	_
21	Cancer	cancer	NN	_	23	com	_	_
22	Institut	institut	NN	_	23	com	_	_
23	e	e	NN	_	17	ppmod	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	NCI	nci	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	and	and	CC	_	23	cc	_	_
28	the	the	DT	_	30	det	_	_
29	Japanese	japanese	JJ	_	30	attr	_	_
30	Foundation	foundation	NN	_	23	conj	_	_
31	for	for	IN	_	33	case	_	_
32	Cancer	cancer	NN	_	33	com	_	_
33	Research	research	NN	_	30	ppmod	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	JFCR	jfcr	NN	_	33	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	:	:	:	_	8	p	_	_
38	drug1	drug0	NN	_	8	appo	_	_
39	(	-lrb-	-LRB-	_	40	p	_	_
40	R48G	r0g	NNP	_	38	prn	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	,	,	,	_	38	p	_	_
43	drug2	drug0	NN	_	38	conj	_	_
44	(	-lrb-	-LRB-	_	45	p	_	_
45	A119S	a0s	NNP	_	43	prn	_	_
46	)	-rrb-	-RRB-	_	45	p	_	_
47	,	,	,	_	43	p	_	_
48	drug3	drug0	NN	_	38	conj	_	_
49	(	-lrb-	-LRB-	_	50	p	_	_
50	L432V	l0v	NNP	_	48	prn	_	_
51	)	-rrb-	-RRB-	_	50	p	_	_
52	,	,	,	_	48	p	_	_
53	and	and	CC	_	48	cc	_	_
54	drug4	drug0	NN	_	38	conj	_	_
55	(	-lrb-	-LRB-	_	56	p	_	_
56	N453S	n0s	NN	_	38	prn	_	_
57	)	-rrb-	-RRB-	_	56	p	_	_
58	.	.	.	_	3	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Evidence	evidence	NN	_	5	dep	_	_
4	has	have	VBZ	_	5	aux	_	_
5	suggested	suggest	VBN	_	1	acl	_	_
6	that	that	IN	_	16	mark	_	_
7	tumour	tumour	NN	_	9	com	_	_
8	necrosis	necrosis	NN	_	9	com	_	_
9	factor	factor	NN	_	13	attr	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	TNF	tnf	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	-a	-a	NN	_	16	dep	_	_
14	may	may	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	involved	involve	VBN	_	5	comp	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	aetiology	aetiology	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	16	p	_	_
23	but	but	CC	_	16	cc	_	_
24	the	the	DT	_	26	det	_	_
25	underlying	underlying	JJ	_	26	attr	_	_
26	association	association	NN	_	47	dep	_	_
27	of	of	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	TNF-a	tnf-a	NN	_	30	com	_	_
30	polymorphisms	polymorphism	NNS	_	26	ppmod	_	_
31	-238G/A	0g/a	NN	_	30	attr	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	drug1	drug0	NN	_	31	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	and	and	CC	_	31	cc	_	_
36	-308G/A	0g/a	NN	_	31	conj	_	_
37	(	-lrb-	-LRB-	_	38	p	_	_
38	drug2	drug0	NN	_	36	prn	_	_
39	)	-rrb-	-RRB-	_	38	p	_	_
40	with	with	IN	_	42	case	_	_
41	the	the	DT	_	42	det	_	_
42	risk	risk	NN	_	26	ppmod	_	_
43	of	of	IN	_	44	case	_	_
44	drug4	drug0	NN	_	42	ppmod	_	_
45	is	be	VBZ	_	47	aux	_	_
46	still	still	RB	_	47	adv	_	_
47	unconfirmed	unconfirmed	VBN	_	16	conj	_	_
48	.	.	.	_	1	p	_	_

1	Evidence	evidence	NN	_	3	dep	_	_
2	has	have	VBZ	_	3	aux	_	_
3	suggested	suggest	VBN	_	0	root	_	_
4	that	that	IN	_	14	mark	_	_
5	tumour	tumour	NN	_	7	com	_	_
6	necrosis	necrosis	NN	_	7	com	_	_
7	factor	factor	NN	_	11	attr	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	TNF	tnf	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	-a	-a	NN	_	14	dep	_	_
12	may	may	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	involved	involve	VBN	_	3	comp	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	aetiology	aetiology	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	psoriasis	psoriasis	NN	_	17	ppmod	_	_
20	,	,	,	_	14	p	_	_
21	but	but	CC	_	14	cc	_	_
22	the	the	DT	_	24	det	_	_
23	underlying	underlying	JJ	_	24	attr	_	_
24	association	association	NN	_	39	dep	_	_
25	of	of	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	TNF-a	tnf-a	NN	_	28	com	_	_
28	polymorphisms	polymorphism	NNS	_	24	ppmod	_	_
29	-238G/A	0g/a	NN	_	30	com	_	_
30	drug1	drug0	NN	_	28	attr	_	_
31	and	and	CC	_	30	cc	_	_
32	-308G/A	0g/a	NN	_	33	com	_	_
33	drug2	drug0	NN	_	30	conj	_	_
34	with	with	IN	_	36	case	_	_
35	the	the	DT	_	36	det	_	_
36	risk	risk	NN	_	24	ppmod	_	_
37	of	of	IN	_	38	case	_	_
38	drug3	drug0	NN	_	36	ppmod	_	_
39	is	be	VBZ	_	14	conj	_	_
40	still	still	RB	_	39	adv	_	_
41	<ModMar>unconfirmed<ModMar>	<modmar>unconfirmed<modmar>	NN	_	39	obj	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	We	we	PRP	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	confirmed	confirm	VBN	_	1	acl	_	_
6	associations	association	NNS	_	5	obj	_	_
7	between	between	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug1	drug0	NN	_	8	conj	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	.	.	.	_	1	p	_	_

1	Objective	objective	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	We	we	PRP	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	conducted	conduct	VBN	_	1	acl	_	_
6	the	the	DT	_	8	det	_	_
7	first	#ord#	JJ	_	8	attr	_	_
8	study	study	NN	_	5	obj	_	_
9	of	of	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	association	association	NN	_	8	ppmod	_	_
12	of	of	IN	_	15	case	_	_
13	interleukin	interleukin	NN	_	15	attr	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	IL	il	NN	_	11	ppmod	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	-10	0	CD	_	15	num	_	_
18	,	,	,	_	15	p	_	_
19	tumor	tumor	NN	_	22	com	_	_
20	necrosis	necrosis	NN	_	22	com	_	_
21	factor	factor	NN	_	22	com	_	_
22	alpha	alpha	NN	_	15	conj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	TNF-a	tnf-a	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	,	,	,	_	22	p	_	_
27	and	and	CC	_	22	cc	_	_
28	drug1	drug0	JJ	_	32	attr	_	_
29	region	region	NN	_	32	attr	_	_
30	single	single	JJ	_	32	attr	_	_
31	nucleotide	nucleotide	NN	_	32	com	_	_
32	polymorphisms	polymorphism	NNS	_	15	conj	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	SNPs	snp	NNS	_	32	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	with	with	IN	_	37	case	_	_
37	drug2	drug0	NN	_	11	ppmod	_	_
38	in	in	IN	_	40	case	_	_
39	Western	western	NN	_	40	com	_	_
40	Algeria	algeria	NN	_	37	ppmod	_	_
41	.	.	.	_	1	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	results	result	NNS	_	3	dep	_	_
3	show	show	VBP	_	0	root	_	_
4	a	a	DT	_	6	det	_	_
5	potential	potential	JJ	_	6	attr	_	_
6	influence	influence	NN	_	3	obj	_	_
7	of	of	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	deletion	deletion	NN	_	6	ppmod	_	_
11	on	on	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	risk	risk	NN	_	6	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	disease	disease	NN	_	13	ppmod	_	_
17	among	among	IN	_	18	case	_	_
18	patients	patient	NNS	_	13	ppmod	_	_
19	with	with	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	3	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	association	association	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	4	ppmod	_	_
9	in	in	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	combined	combined	JJ	_	12	attr	_	_
12	sample	sample	NN	_	2	ppmod	_	_
13	(	-lrb-	-LRB-	_	18	p	_	_
14	n=4071	n=0	NN	_	18	dep	_	_
15	,	,	,	_	18	p	_	_
16	p=0.110	p=0	NN	_	18	dep	_	_
17	,	,	,	_	18	p	_	_
18	odds	odds	NNS	_	12	prn	_	_
19	ratio=1.08	ratio=0	CD	_	18	num	_	_
20	)	-rrb-	-RRB-	_	18	p	_	_
21	.	.	.	_	2	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	results	result	NNS	_	5	dep	_	_
3	do	do	VBP	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	support	support	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	association	association	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	7	ppmod	_	_
12	in	in	IN	_	16	case	_	_
13	the	the	DT	_	16	det	_	_
14	Han	han	JJ	_	16	attr	_	_
15	Chinese	chinese	JJ	_	16	attr	_	_
16	population	population	NN	_	11	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Genotypes	genotype	NNS	_	23	dep	_	_
4	of	of	IN	_	8	case	_	_
5	tumor	tumor	NN	_	8	com	_	_
6	necrosis	necrosis	NN	_	8	com	_	_
7	factor	factor	NN	_	8	com	_	_
8	alpha	alpha	NN	_	3	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	TNF-a	tnf-a	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	and	and	CC	_	8	cc	_	_
13	its	its	PRP$	_	15	poss	_	_
14	surface	surface	NN	_	15	com	_	_
15	receptors	receptor	NNS	_	8	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug1	drug0	NN	_	15	appo	_	_
18	and	and	CC	_	17	cc	_	_
19	drug2	drug0	NN	_	17	conj	_	_
20	,	,	,	_	15	p	_	_
21	have	have	VBP	_	23	aux	_	_
22	been	be	VBN	_	23	aux	_	_
23	examined	examine	VBN	_	45	advcl	_	_
24	in	in	IN	_	25	case	_	_
25	terms	term	NNS	_	23	ppmod	_	_
26	of	of	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	progression	progression	NN	_	25	ppmod	_	_
29	,	,	,	_	28	p	_	_
30	metastasis	metastasis	NN	_	28	conj	_	_
31	,	,	,	_	30	p	_	_
32	clinical	clinical	JJ	_	33	attr	_	_
33	efficacy	efficacy	NN	_	28	conj	_	_
34	,	,	,	_	33	p	_	_
35	and	and	CC	_	33	cc	_	_
36	prognosis	prognosis	NN	_	28	conj	_	_
37	of	of	IN	_	39	case	_	_
38	various	various	JJ	_	39	attr	_	_
39	cancers	cancer	NNS	_	28	ppmod	_	_
40	;	;	:	_	45	p	_	_
41	however	however	RB	_	45	adv	_	_
42	,	,	,	_	45	p	_	_
43	little	little	JJ	_	45	dep	_	_
44	is	be	VBZ	_	45	aux	_	_
45	known	know	VBN	_	1	acl	_	_
46	about	about	IN	_	48	case	_	_
47	their	their	PRP$	_	48	poss	_	_
48	effects	effect	NNS	_	45	ppmod	_	_
49	on	on	IN	_	51	case	_	_
50	clinical	clinical	JJ	_	51	attr	_	_
51	outcome	outcome	NN	_	48	ppmod	_	_
52	in	in	IN	_	53	case	_	_
53	patients	patient	NNS	_	51	ppmod	_	_
54	with	with	IN	_	55	case	_	_
55	drug3	drug0	NN	_	53	ppmod	_	_
56	(	-lrb-	-LRB-	_	57	p	_	_
57	ESCC	escc	NN	_	55	prn	_	_
58	)	-rrb-	-RRB-	_	57	p	_	_
59	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	genotype	genotype	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	predictive	predictive	JJ	_	3	dep	_	_
5	of	of	IN	_	7	case	_	_
6	clinical	clinical	JJ	_	7	attr	_	_
7	response	response	NN	_	4	ppmod	_	_
8	after	after	IN	_	9	case	_	_
9	treatment	treatment	NN	_	7	ppmod	_	_
10	with	with	IN	_	13	case	_	_
11	definitive	definitive	JJ	_	13	attr	_	_
12	5-fluorouracil/cisplatin-based	0-fluorouracil/cisplatin-based	JJ	_	13	attr	_	_
13	chemoradiotherapy	chemoradiotherapy	NN	_	9	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	Japanese	japanese	JJ	_	16	attr	_	_
16	patients	patient	NNS	_	13	ppmod	_	_
17	with	with	IN	_	21	case	_	_
18	esophageal	esophageal	JJ	_	21	attr	_	_
19	squamous	squamous	JJ	_	21	attr	_	_
20	cell	cell	NN	_	21	com	_	_
21	drug2	drug0	NN	_	16	ppmod	_	_
22	.	.	.	_	3	p	_	_

1	Overall	overall	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	TNF-a	tnf-a	NN	_	5	com	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	polymorphism	polymorphism	NN	_	8	dep	_	_
6	was	be	VBD	_	8	aux	_	_
7	significantly	significantly	RB	_	8	adv	_	_
8	associated	associate	VBN	_	0	root	_	_
9	with	with	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	increased	increase	VBN	_	12	attr	_	_
12	risk	risk	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	under	under	IN	_	19	case	_	_
16	four	#crd#	CD	_	19	num	_	_
17	genetic	genetic	JJ	_	19	attr	_	_
18	comparison	comparison	NN	_	19	com	_	_
19	models	model	NNS	_	8	ppmod	_	_

1	Remarkably	remarkably	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	was	be	VBD	_	0	root	_	_
5	a	a	DT	_	7	det	_	_
6	protective	protective	JJ	_	7	attr	_	_
7	factor	factor	NN	_	4	obj	_	_
8	to	to	TO	_	9	aux	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	when	when	WRB	_	11	adv	_	_
11	compared	compare	VBN	_	4	comp	_	_
12	with	with	IN	_	13	case	_	_
13	BPH	bph	NN	_	11	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	OR=0.550	or=0	NN	_	4	prn	_	_
16	;	;	:	_	15	p	_	_
17	95	0	CD	_	19	num	_	_
18	%	%	NN	_	19	meta	_	_
19	CI=0.311-0.975	ci=0	CD	_	15	appo	_	_
20	)	-rrb-	-RRB-	_	15	p	_	_
21	,	,	,	_	4	p	_	_
22	although	although	IN	_	28	mark	_	_
23	the	the	DT	_	26	det	_	_
24	statistically	statistically	RB	_	25	adv	_	_
25	significant	significant	JJ	_	26	attr	_	_
26	difference	difference	NN	_	28	dep	_	_
27	was	be	VBD	_	28	aux	_	_
28	lost	lose	VBN	_	4	comp	_	_
29	after	after	IN	_	30	case	_	_
30	correction	correction	NN	_	28	ppmod	_	_
31	for	for	IN	_	33	case	_	_
32	multiple	multiple	JJ	_	33	attr	_	_
33	comparisons	comparison	NNS	_	30	ppmod	_	_
34	.	.	.	_	4	p	_	_

1	No	no	DT	_	3	det	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	associations	association	NNS	_	8	dep	_	_
4	of	of	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	variant	variant	NN	_	3	ppmod	_	_
7	were	be	VBD	_	8	aux	_	_
8	observed	observe	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	or	or	CC	_	12	cc	_	_
14	drug4	drug0	NN	_	16	com	_	_
15	clinicopathologic	clinicopathologic	NN	_	16	com	_	_
16	status	status	NN	_	10	conj	_	_
17	.	.	.	_	8	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	determined	determine	VBN	_	0	root	_	_
4	4	0	CD	_	8	num	_	_
5	frequent	frequent	JJ	_	8	attr	_	_
6	nonsynonymous	nonsynonymous	JJ	_	8	attr	_	_
7	gene	gene	NN	_	8	com	_	_
8	polymorphisms	polymorphism	NNS	_	3	obj	_	_
9	of	of	IN	_	10	case	_	_
10	CYP1B1	cyp0b0	NN	_	8	ppmod	_	_
11	in	in	IN	_	16	case	_	_
12	the	the	DT	_	16	det	_	_
13	human	human	JJ	_	16	attr	_	_
14	tumor	tumor	NN	_	16	com	_	_
15	cell	cell	NN	_	16	com	_	_
16	lines	line	NNS	_	10	ppmod	_	_
17	panels	panel	NNS	_	8	appo	_	_
18	of	of	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	National	national	JJ	_	21	attr	_	_
21	CancerInstitute	cancerinstitute	NN	_	17	ppmod	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	NCI	nci	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	and	and	CC	_	21	cc	_	_
26	the	the	DT	_	28	det	_	_
27	Japanese	japanese	JJ	_	28	attr	_	_
28	Foundation	foundation	NN	_	21	conj	_	_
29	for	for	IN	_	31	case	_	_
30	drug5	drug0	NN	_	31	com	_	_
31	Research	research	NN	_	28	ppmod	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	JFCR	jfcr	NN	_	28	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	:	:	:	_	8	p	_	_
36	drug1	drug0	NN	_	8	appo	_	_
37	(	-lrb-	-LRB-	_	38	p	_	_
38	R48G	r0g	NNP	_	36	prn	_	_
39	)	-rrb-	-RRB-	_	38	p	_	_
40	,	,	,	_	36	p	_	_
41	drug2	drug0	NN	_	36	conj	_	_
42	(	-lrb-	-LRB-	_	43	p	_	_
43	A119S	a0s	NNP	_	41	prn	_	_
44	)	-rrb-	-RRB-	_	43	p	_	_
45	,	,	,	_	41	p	_	_
46	drug3	drug0	NN	_	36	conj	_	_
47	(	-lrb-	-LRB-	_	48	p	_	_
48	L432V	l0v	NNP	_	46	prn	_	_
49	)	-rrb-	-RRB-	_	48	p	_	_
50	,	,	,	_	46	p	_	_
51	and	and	CC	_	46	cc	_	_
52	drug4	drug0	NN	_	36	conj	_	_
53	(	-lrb-	-LRB-	_	54	p	_	_
54	N453S	n0s	NN	_	36	prn	_	_
55	)	-rrb-	-RRB-	_	54	p	_	_

1	Seven	#crd#	CD	_	3	num	_	_
2	polymorphic	polymorphic	JJ	_	3	attr	_	_
3	variants	variant	NNS	_	20	dep	_	_
4	in	in	IN	_	5	case	_	_
5	genes	gene	NNS	_	3	ppmod	_	_
6	drug1	drug0	NN	_	5	attr	_	_
7	,	,	,	_	6	p	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	6	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	6	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug5	drug0	NN	_	6	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug6	drug0	NN	_	6	conj	_	_
17	and	and	CC	_	16	cc	_	_
18	drug7	drug0	NN	_	6	conj	_	_
19	were	be	VBD	_	20	aux	_	_
20	associated	associate	VBN	_	0	root	_	_
21	with	with	IN	_	22	case	_	_
22	drug8	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	20	p	_	_

1	Noteworthy	noteworthy	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	the	the	DT	_	5	det	_	_
4	considerable	considerable	JJ	_	5	attr	_	_
5	number	number	NN	_	13	dep	_	_
6	of	of	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	carrying	carry	VBG	_	7	acl	_	_
9	drug1	drug0	NN	_	12	attr	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	alleles	allele	NNS	_	8	obj	_	_
13	underlies	underlie	VBZ	_	0	root	_	_
14	the	the	DT	_	15	det	_	_
15	importance	importance	NN	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	considering	consider	VBG	_	15	ppmod	_	_
18	pharmacogenetic	pharmacogenetic	JJ	_	19	attr	_	_
19	testing	testing	NN	_	17	obj	_	_
20	before	before	IN	_	21	case	_	_
21	starting	start	VBG	_	19	ppmod	_	_
22	drug	drug	NN	_	23	com	_	_
23	therapy	therapy	NN	_	21	obj	_	_
24	protocols	protocol	NNS	_	26	dep	_	_
25	to	to	TO	_	26	aux	_	_
26	prevent	prevent	VB	_	21	comp	_	_
27	toxicity	toxicity	NN	_	26	obj	_	_
28	and/or	and/or	CC	_	27	cc	_	_
29	lack	lack	NN	_	27	conj	_	_
30	of	of	IN	_	31	case	_	_
31	effectiveness	effectiveness	NN	_	29	ppmod	_	_
32	in	in	IN	_	33	case	_	_
33	drug3	drug0	NN	_	29	ppmod	_	_
34	or	or	CC	_	33	cc	_	_
35	drug4	drug0	NN	_	37	com	_	_
36	virus	virus	NN	_	37	com	_	_
37	infections	infection	NNS	_	33	conj	_	_
38	.	.	.	_	13	p	_	_

1	Logistic	logistic	JJ	_	3	attr	_	_
2	regression	regression	NN	_	3	com	_	_
3	analysis	analysis	NN	_	4	dep	_	_
4	identified	identify	VBD	_	0	root	_	_
5	two	#crd#	CD	_	6	num	_	_
6	variants	variant	NNS	_	4	obj	_	_
7	associated	associate	VBN	_	6	acl	_	_
8	with	with	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	6	p	_	_
11	the	the	DT	_	13	det	_	_
12	32-bp	0-bp	JJ	_	13	attr	_	_
13	deletion	deletion	NN	_	6	conj	_	_
14	within	within	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	13	cc	_	_
17	the	the	DT	_	18	det	_	_
18	drug2	drug0	NN	_	6	conj	_	_
19	within	within	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	MTHFR	mthfr	NN	_	22	com	_	_
22	gene	gene	NN	_	18	ppmod	_	_
23	.	.	.	_	4	p	_	_

1	Univariate	univariate	JJ	_	2	attr	_	_
2	analysis	analysis	NN	_	3	dep	_	_
3	detected	detect	VBD	_	0	root	_	_
4	one	#crd#	CD	_	7	num	_	_
5	significant	significant	JJ	_	7	attr	_	_
6	single-nucleotide	single-nucleotide	NN	_	7	com	_	_
7	polymorphism	polymorphism	NN	_	3	obj	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	p	p	NN	_	7	prn	_	_
10	=	=	JJ	_	9	attr	_	_
11	0.03	0	CD	_	9	num	_	_
12	)	-rrb-	-RRB-	_	9	p	_	_
13	,	,	,	_	7	p	_	_
14	drug1	drug0	NN	_	7	appo	_	_
15	,	,	,	_	7	p	_	_
16	within	within	IN	_	23	case	_	_
17	the	the	DT	_	23	det	_	_
18	methylenetetrahydrofolate	methylenetetrahydrofolate	NN	_	19	com	_	_
19	reductase	reductase	NN	_	23	attr	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	MTHFR	mthfr	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	gene	gene	NN	_	7	ppmod	_	_
24	associated	associate	VBN	_	23	acl	_	_
25	with	with	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	3	p	_	_

1	Logistic	logistic	JJ	_	3	attr	_	_
2	regression	regression	NN	_	3	com	_	_
3	analysis	analysis	NN	_	4	dep	_	_
4	identified	identify	VBD	_	0	root	_	_
5	two	#crd#	CD	_	6	num	_	_
6	variants	variant	NNS	_	4	obj	_	_
7	associated	associate	VBN	_	6	acl	_	_
8	with	with	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	6	p	_	_
11	the	the	DT	_	13	det	_	_
12	32-bp	0-bp	JJ	_	13	attr	_	_
13	deletion	deletion	NN	_	6	conj	_	_
14	within	within	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	13	cc	_	_
17	the	the	DT	_	19	det	_	_
18	p.222A/V	p.0a/v	NN	_	19	com	_	_
19	variant	variant	NN	_	6	conj	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	drug2	drug0	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	within	within	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	MTHFR	mthfr	NN	_	26	com	_	_
26	gene	gene	NN	_	19	ppmod	_	_
27	.	.	.	_	4	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	explored	explore	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	influence	influence	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	interactions	interaction	NNS	_	4	ppmod	_	_
7	between	between	IN	_	8	case	_	_
8	polymorphisms	polymorphism	NNS	_	6	ppmod	_	_
9	acting	act	VBG	_	8	acl	_	_
10	upon	upon	IN	_	12	case	_	_
11	postsynaptic	postsynaptic	JJ	_	12	attr	_	_
12	receptors	receptor	NNS	_	9	ppmod	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	DRD2	drd0	NN	_	16	com	_	_
15	TaqA1	taqa0	NN	_	16	com	_	_
16	drug1	drug0	NN	_	12	prn	_	_
17	and	and	CC	_	16	cc	_	_
18	DRD4	drd0	JJ	_	19	attr	_	_
19	7R	0r	NN	_	16	conj	_	_
20	)	-rrb-	-RRB-	_	16	p	_	_
21	and	and	CC	_	12	cc	_	_
22	dopamine	dopamine	NN	_	23	com	_	_
23	regulators	regulator	NNS	_	12	conj	_	_
24	(	-lrb-	-LRB-	_	26	p	_	_
25	COMT	comt	NN	_	26	com	_	_
26	drug2	drug0	NN	_	23	prn	_	_
27	and	and	CC	_	26	cc	_	_
28	DAT1	dat0	NN	_	26	conj	_	_
29	)	-rrb-	-RRB-	_	26	p	_	_
30	on	on	IN	_	32	case	_	_
31	the	the	DT	_	32	det	_	_
32	expression	expression	NN	_	4	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	drug3	drug0	NN	_	32	ppmod	_	_
35	and	and	CC	_	34	cc	_	_
36	personality	personality	NN	_	37	com	_	_
37	traits	trait	NNS	_	34	conj	_	_
38	in	in	IN	_	39	case	_	_
39	women	woman	NNS	_	32	ppmod	_	_
40	with	with	IN	_	41	case	_	_
41	drug4	drug0	NN	_	39	ppmod	_	_
42	.	.	.	_	2	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	observed	observe	VBD	_	19	advcl	_	_
3	two	#crd#	CD	_	5	num	_	_
4	epistatic	epistatic	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	2	obj	_	_
6	on	on	IN	_	8	case	_	_
7	symptom	symptom	NN	_	8	com	_	_
8	indices	index	NNS	_	5	ppmod	_	_
9	:	:	:	_	19	p	_	_
10	interactions	interaction	NNS	_	19	dep	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	in	in	IN	_	14	case	_	_
13	predicted	predict	VBN	_	14	attr	_	_
14	directions	direction	NNS	_	10	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	10	ppmod	_	_
18	were	be	VBD	_	19	aux	_	_
19	seen	see	VBN	_	0	root	_	_
20	on	on	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	p=.023	p=.0	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	,	,	,	_	21	p	_	_
26	and	and	CC	_	21	cc	_	_
27	of	of	IN	_	28	case	_	_
28	drug2	drug0	NN	_	30	ppmod	_	_
29	on	on	IN	_	30	case	_	_
30	drug4	drug0	NN	_	21	conj	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	p=.014	p=.0	NN	_	30	prn	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	,	,	,	_	19	p	_	_

1	STUDY	study	NN	_	2	com	_	_
2	PURPOSES	purpose	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	,	,	,	_	2	p	_	_
5	Analysis	analysis	NN	_	2	conj	_	_
6	of	of	IN	_	7	case	_	_
7	influence	influence	NN	_	5	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	allelic	allelic	JJ	_	10	attr	_	_
10	polymorphisms	polymorphism	NNS	_	7	ppmod	_	_
11	C1444T	c0t	NNP	_	44	attr	_	_
12	of	of	IN	_	15	case	_	_
13	CRP	crp	NN	_	15	com	_	_
14	gene	gene	NN	_	15	com	_	_
15	drug1	drug0	NN	_	44	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	G	g	NN	_	21	attr	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	-174	0	CD	_	21	num	_	_
20	)	-rrb-	-RRB-	_	21	p	_	_
21	A	a	NN	_	15	appo	_	_
22	of	of	IN	_	25	case	_	_
23	IL6	il0	NN	_	25	com	_	_
24	gene	gene	NN	_	25	com	_	_
25	drug2	drug0	NN	_	21	ppmod	_	_
26	,	,	,	_	15	p	_	_
27	A	a	DT	_	31	det	_	_
28	(	-lrb-	-LRB-	_	31	p	_	_
29	-308	0	CD	_	31	num	_	_
30	)	-rrb-	-RRB-	_	31	p	_	_
31	G	g	NN	_	15	appo	_	_
32	of	of	IN	_	35	case	_	_
33	TNF	tnf	NN	_	35	com	_	_
34	gene	gene	NN	_	35	com	_	_
35	drug3	drug0	NN	_	31	ppmod	_	_
36	,	,	,	_	15	p	_	_
37	G252A	g0a	NNP	_	15	appo	_	_
38	of	of	IN	_	41	case	_	_
39	LTA	lta	NN	_	41	com	_	_
40	gene	gene	NN	_	41	com	_	_
41	drug4	drug0	NN	_	37	ppmod	_	_
42	,	,	,	_	15	p	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	-509	0	CD	_	10	appo	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	of	of	IN	_	49	case	_	_
47	TGFB1	tgfb0	NN	_	49	com	_	_
48	gene	gene	NN	_	49	com	_	_
49	drug5	drug0	NN	_	7	ppmod	_	_
50	and	and	CC	_	5	cc	_	_
51	delta32	delta0	NN	_	2	conj	_	_
52	(	-lrb-	-LRB-	_	53	p	_	_
53	w/d	w/d	NN	_	51	prn	_	_
54	)	-rrb-	-RRB-	_	53	p	_	_
55	of	of	IN	_	58	case	_	_
56	CCR5	ccr0	NN	_	58	com	_	_
57	gene	gene	NN	_	58	com	_	_
58	drug6	drug0	NN	_	51	ppmod	_	_
59	on	on	IN	_	60	case	_	_
60	development	development	NN	_	51	ppmod	_	_
61	of	of	IN	_	62	case	_	_
62	drug7	drug0	NN	_	60	ppmod	_	_
63	in	in	IN	_	65	case	_	_
64	Russian	russian	JJ	_	65	attr	_	_
65	patients	patient	NNS	_	62	ppmod	_	_
66	with	with	IN	_	67	case	_	_
67	MI	mi	NN	_	65	ppmod	_	_
68	during	during	IN	_	71	case	_	_
69	two	#crd#	CD	_	70	num	_	_
70	years	year	NNS	_	71	com	_	_
71	follow-up	follow-up	NN	_	62	ppmod	_	_

1	Methods	method	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	4	det	_	_
4	total	total	NN	_	19	dep	_	_
5	of	of	IN	_	8	case	_	_
6	51	0	CD	_	8	num	_	_
7	drug12	drug0	NN	_	8	com	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	96	0	CD	_	12	num	_	_
11	unrelated	unrelated	JJ	_	12	attr	_	_
12	controls	control	NNS	_	8	conj	_	_
13	from	from	IN	_	15	case	_	_
14	West	west	NNP	_	15	com	_	_
15	region	region	NN	_	8	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	Algeria	algeria	NNP	_	15	ppmod	_	_
18	were	be	VBD	_	19	aux	_	_
19	genotyped	genotyped	VBN	_	1	acl	_	_
20	by	by	IN	_	22	case	_	_
21	direct	direct	JJ	_	22	attr	_	_
22	sequencing	sequencing	NN	_	19	ppmod	_	_
23	for	for	IN	_	25	case	_	_
24	11	0	CD	_	25	num	_	_
25	SNPs	snp	NNS	_	22	ppmod	_	_
26	including	include	VBG	_	28	adv	_	_
27	2	0	CD	_	28	num	_	_
28	SNPs	snp	NNS	_	25	ppmod	_	_
29	from	from	IN	_	36	case	_	_
30	the	the	DT	_	36	det	_	_
31	IL10	il0	NN	_	36	com	_	_
32	promoter	promoter	NN	_	36	com	_	_
33	-LSB-c.-819T	-lsb-c.-0t	NN	_	36	com	_	_
34	>	>	NN	_	36	com	_	_
35	C	c	NN	_	36	com	_	_
36	drug1	drug0	NN	_	28	ppmod	_	_
37	,	,	,	_	28	p	_	_
38	c.-592A	c.-0a	NN	_	41	com	_	_
39	>	>	NN	_	41	com	_	_
40	C	c	NN	_	41	com	_	_
41	drug2	drug0	NN	_	28	appo	_	_
42	,	,	,	_	41	p	_	_
43	6	0	CD	_	44	num	_	_
44	SNPs	snp	NNS	_	41	conj	_	_
45	from	from	IN	_	52	case	_	_
46	the	the	DT	_	52	det	_	_
47	TNF-a	tnf-a	NN	_	52	com	_	_
48	promoter	promoter	NN	_	52	com	_	_
49	-LSB-c.-1211T	-lsb-c.-0t	NN	_	52	com	_	_
50	>	>	NN	_	52	com	_	_
51	C	c	NN	_	52	com	_	_
52	drug3	drug0	NN	_	44	ppmod	_	_
53	,	,	,	_	44	p	_	_
54	c.-1043C	c.-0c	NN	_	55	com	_	_
55	drug4	drug0	NN	_	41	conj	_	_
56	,	,	,	_	55	p	_	_
57	c.-1037C	c.-0c	NN	_	60	com	_	_
58	>	>	NN	_	60	com	_	_
59	T	t	NN	_	60	com	_	_
60	drug5	drug0	NN	_	41	conj	_	_
61	,	,	,	_	60	p	_	_
62	c.-556G	c.-0g	NN	_	65	com	_	_
63	>	>	NN	_	65	com	_	_
64	A	a	NN	_	65	com	_	_
65	drug6	drug0	NN	_	41	conj	_	_
66	,	,	,	_	65	p	_	_
67	c.-488G	c.-0g	NN	_	70	com	_	_
68	>	>	NN	_	70	com	_	_
69	A	a	NN	_	70	com	_	_
70	drug7	drug0	NN	_	41	conj	_	_
71	,	,	,	_	70	p	_	_
72	and	and	CC	_	70	cc	_	_
73	c.-418G	c.-0g	NN	_	76	com	_	_
74	>	>	NN	_	76	com	_	_
75	A	a	NN	_	76	com	_	_
76	drug8	drug0	NN	_	41	conj	_	_
77	]	-rsb-	-RRB-	_	76	p	_	_
78	,	,	,	_	28	p	_	_
79	and	and	CC	_	28	cc	_	_
80	3	0	CD	_	81	num	_	_
81	SNPs	snp	NNS	_	28	conj	_	_
82	from	from	IN	_	88	case	_	_
83	the	the	DT	_	88	det	_	_
84	IL23R-IL12RB2	il0r-il0rb0	NN	_	88	com	_	_
85	region	region	NN	_	88	com	_	_
86	-LSB-g.67747415A	-lsb-g.0a	NN	_	88	com	_	_
87	>	>	NN	_	88	com	_	_
88	C	c	NN	_	81	ppmod	_	_
89	drug9	drug0	CD	_	88	num	_	_
90	,	,	,	_	88	p	_	_
91	g.67740092G	g.0g	NN	_	93	com	_	_
92	>	>	NN	_	93	com	_	_
93	A	a	NN	_	88	conj	_	_
94	drug10	drug0	CD	_	93	num	_	_
95	,	,	,	_	93	p	_	_
96	and	and	CC	_	93	cc	_	_
97	g.67760140T	g.0t	NN	_	99	com	_	_
98	>	>	NN	_	99	com	_	_
99	C	c	NN	_	88	conj	_	_
100	drug11	drug0	CD	_	99	num	_	_
101	]	-rsb-	-RRB-	_	99	p	_	_
102	.	.	.	_	1	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	VARIOUS	various	JJ	_	4	attr	_	_
4	SNPS	snp	NNS	_	5	dep	_	_
5	REACHED	reach	VBD	_	1	acl	_	_
6	NOMINAL	nominal	JJ	_	7	attr	_	_
7	SIGNIFICANCE	significance	NN	_	5	dat	_	_
8	:	:	:	_	5	p	_	_
9	drug12	drug0	CD	_	5	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	drug13	drug0	CD	_	9	conj	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	9	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	,	,	,	_	9	p	_	_
17	drug14	drug0	CD	_	9	conj	_	_
18	with	with	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	17	p	_	_
21	drug15	drug0	CD	_	9	conj	_	_
22	with	with	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	,	,	,	_	21	p	_	_
25	drug16	drug0	CD	_	9	conj	_	_
26	with	with	IN	_	27	case	_	_
27	drug5	drug0	NN	_	25	ppmod	_	_
28	and	and	CC	_	27	cc	_	_
29	drug6	drug0	NN	_	27	conj	_	_
30	,	,	,	_	25	p	_	_
31	drug17	drug0	CD	_	9	conj	_	_
32	with	with	IN	_	33	case	_	_
33	drug7	drug0	NN	_	31	ppmod	_	_
34	,	,	,	_	31	p	_	_
35	drug18	drug0	CD	_	9	conj	_	_
36	with	with	IN	_	37	case	_	_
37	drug8	drug0	NN	_	35	ppmod	_	_
38	,	,	,	_	35	p	_	_
39	drug19	drug0	CD	_	9	conj	_	_
40	with	with	IN	_	41	case	_	_
41	drug9	drug0	NN	_	39	ppmod	_	_
42	,	,	,	_	39	p	_	_
43	drug10	drug0	CD	_	9	conj	_	_
44	and	and	CC	_	43	cc	_	_
45	drug11	drug0	CD	_	9	conj	_	_
46	.	.	.	_	1	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	found	find	VBD	_	34	advcl	_	_
3	a	a	DT	_	6	det	_	_
4	significant	significant	JJ	_	6	attr	_	_
5	genotype	genotype	NN	_	6	com	_	_
6	effect	effect	NN	_	2	obj	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	all	all	NN	_	6	prn	_	_
9	P<0.017	p<0	CD	_	8	num	_	_
10	)	-rrb-	-RRB-	_	8	p	_	_
11	for	for	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	following	following	JJ	_	15	attr	_	_
14	smoking-related	smoking-related	JJ	_	15	attr	_	_
15	phenotypes	phenotype	NNS	_	6	ppmod	_	_
16	:	:	:	_	34	p	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	i	i	LS	_	21	meta	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	cigarettes	cigarette	NNS	_	21	dep	_	_
21	smoked	smoke	VBN	_	34	advcl	_	_
22	per	per	IN	_	23	case	_	_
23	day	day	NN	_	21	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	CYP2A13	cyp0a0	NN	_	26	com	_	_
26	*	*	NN	_	23	conj	_	_
27	3	0	CD	_	26	num	_	_
28	;	;	:	_	34	p	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	ii	ii	LS	_	34	meta	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	pack	pack	NN	_	33	com	_	_
33	years	year	NNS	_	34	dep	_	_
34	smoked	smoke	VBD	_	0	root	_	_
35	and	and	CC	_	37	cc	_	_
36	CYP2A6	cyp0a0	NN	_	37	com	_	_
37	*	*	NN	_	34	obj	_	_
38	2	0	CD	_	37	num	_	_
39	,	,	,	_	37	p	_	_
40	CYP2A6	cyp0a0	NN	_	43	attr	_	_
41	*	*	NN	_	43	attr	_	_
42	1	0	CD	_	43	num	_	_
43	*	*	NN	_	37	conj	_	_
44	2	0	CD	_	43	num	_	_
45	,	,	,	_	43	p	_	_
46	drug1	drug0	NN	_	37	conj	_	_
47	,	,	,	_	46	p	_	_
48	CYP2B6	cyp0b0	NN	_	49	com	_	_
49	*	*	NN	_	37	conj	_	_
50	4	0	CD	_	49	num	_	_
51	and	and	CC	_	49	cc	_	_
52	DRD2-ANKK1	drd0-ankk0	NN	_	53	com	_	_
53	2137G>A	0g>a	NN	_	37	conj	_	_
54	(	-lrb-	-LRB-	_	55	p	_	_
55	Taq1A	taq0a	NN	_	53	prn	_	_
56	)	-rrb-	-RRB-	_	55	p	_	_
57	;	;	:	_	34	p	_	_
58	(	-lrb-	-LRB-	_	59	p	_	_
59	iii	iii	LS	_	61	meta	_	_
60	)	-rrb-	-RRB-	_	59	p	_	_
61	drug3	drug0	NN	_	34	dep	_	_
62	(	-lrb-	-LRB-	_	63	p	_	_
63	assessed	assess	VBN	_	61	prn	_	_
64	with	with	IN	_	67	case	_	_
65	the	the	DT	_	67	det	_	_
66	Fagestrom	fagestrom	NN	_	67	com	_	_
67	test	test	NN	_	63	ppmod	_	_
68	)	-rrb-	-RRB-	_	63	p	_	_
69	and	and	CC	_	61	cc	_	_
70	drug2	drug0	NN	_	61	conj	_	_
71	.	.	.	_	34	p	_	_

1	The	the	DT	_	5	det	_	_
2	best-studied	best-studied	JJ	_	5	attr	_	_
3	functional	functional	JJ	_	5	attr	_	_
4	genetic	genetic	JJ	_	5	attr	_	_
5	variant	variant	NN	_	10	dep	_	_
6	relevant	relevant	JJ	_	5	attr	_	_
7	to	to	TO	_	9	aux	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	treatment	treatment	NN	_	6	ppmod	_	_
10	is	be	VBZ	_	0	root	_	_
11	drug1	drug0	NN	_	10	obj	_	_
12	,	,	,	_	11	p	_	_
13	a	a	DT	_	15	det	_	_
14	single-nucleotide	single-nucleotide	JJ	_	15	attr	_	_
15	polymorphism	polymorphism	NN	_	11	appo	_	_
16	in	in	IN	_	17	case	_	_
17	exon	exon	NN	_	15	ppmod	_	_
18	1	0	CD	_	17	num	_	_
19	of	of	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	OPRM1	oprm0	NN	_	22	com	_	_
22	gene	gene	NN	_	17	ppmod	_	_
23	that	that	WDT	_	24	dep	_	_
24	encodes	encode	VBZ	_	15	relcl	_	_
25	the	the	DT	_	27	det	_	_
26	u-opioid	u-opioid	JJ	_	27	attr	_	_
27	receptor	receptor	NN	_	24	obj	_	_
28	.	.	.	_	10	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	association	association	NN	_	21	dep	_	_
5	between	between	IN	_	14	case	_	_
6	the	the	DT	_	14	det	_	_
7	OPRM1	oprm0	NN	_	14	attr	_	_
8	A118G	a0g	NN	_	14	attr	_	_
9	(	-lrb-	-LRB-	_	14	p	_	_
10	Asn40Asp	asn0asp	NN	_	14	attr	_	_
11	,	,	,	_	14	p	_	_
12	drug1	drug0	NN	_	14	attr	_	_
13	)	-rrb-	-RRB-	_	14	p	_	_
14	polymorphism	polymorphism	NN	_	4	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	and	and	CC	_	16	cc	_	_
18	alcohol	alcohol	NN	_	19	com	_	_
19	consumption	consumption	NN	_	16	conj	_	_
20	was	be	VBD	_	21	aux	_	_
21	analyzed	analyze	VBN	_	1	acl	_	_
22	using	use	VBG	_	21	comp	_	_
23	three	#crd#	CD	_	26	num	_	_
24	different	different	JJ	_	26	attr	_	_
25	population-based	population-based	JJ	_	26	attr	_	_
26	samples	sample	NNS	_	22	obj	_	_
27	:	:	:	_	1	p	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	a	a	LS	_	34	meta	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	a	a	DT	_	34	det	_	_
32	Finnish	finnish	NN	_	34	com	_	_
33	cohort	cohort	NN	_	34	com	_	_
34	study	study	NN	_	1	appo	_	_
35	,	,	,	_	34	p	_	_
36	Health	health	NN	_	34	appo	_	_
37	2000	0	CD	_	36	num	_	_
38	,	,	,	_	34	p	_	_
39	with	with	IN	_	41	case	_	_
40	503	0	CD	_	41	num	_	_
41	participants	participant	NNS	_	34	ppmod	_	_
42	having	have	VBG	_	45	lv	_	_
43	a	a	DT	_	45	det	_	_
44	DSM-IV	dsm-iv	JJ	_	45	attr	_	_
45	diagnosis	diagnosis	NN	_	41	acl	_	_
46	for	for	IN	_	47	case	_	_
47	drug3	drug0	NN	_	45	ppmod	_	_
48	and/or	and/or	CC	_	47	cc	_	_
49	drug4	drug0	NN	_	47	conj	_	_
50	and	and	CC	_	47	cc	_	_
51	506	0	CD	_	52	num	_	_
52	age-	age-	NN	_	47	conj	_	_
53	and	and	CC	_	52	cc	_	_
54	sex-matched	sex-matched	JJ	_	55	attr	_	_
55	controls	control	NNS	_	52	conj	_	_
56	;	;	:	_	34	p	_	_
57	(	-lrb-	-LRB-	_	58	p	_	_
58	b	b	LS	_	63	meta	_	_
59	)	-rrb-	-RRB-	_	58	p	_	_
60	a	a	DT	_	63	det	_	_
61	Finnish	finnish	NN	_	63	com	_	_
62	cohort	cohort	NN	_	63	com	_	_
63	study	study	NN	_	34	conj	_	_
64	,	,	,	_	63	p	_	_
65	FINRISK	finrisk	NN	_	34	conj	_	_
66	(	-lrb-	-LRB-	_	67	p	_	_
67	n	n	NN	_	65	prn	_	_
68	=	=	JJ	_	67	attr	_	_
69	2360	0	CD	_	67	num	_	_
70	)	-rrb-	-RRB-	_	67	p	_	_
71	and	and	CC	_	65	cc	_	_
72	(	-lrb-	-LRB-	_	73	p	_	_
73	c	c	LS	_	79	meta	_	_
74	)	-rrb-	-RRB-	_	73	p	_	_
75	the	the	DT	_	79	det	_	_
76	Helsinki	helsinki	NN	_	79	com	_	_
77	Birth	birth	NN	_	79	com	_	_
78	Cohort	cohort	NN	_	79	com	_	_
79	Study	study	NN	_	34	conj	_	_
80	(	-lrb-	-LRB-	_	81	p	_	_
81	n	n	NN	_	79	prn	_	_
82	=	=	JJ	_	81	attr	_	_
83	1384	0	CD	_	81	num	_	_
84	)	-rrb-	-RRB-	_	81	p	_	_
85	.	.	.	_	1	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	case-control	case-control	JJ	_	4	attr	_	_
4	study	study	NN	_	34	ppmod	_	_
5	that	that	WDT	_	6	dep	_	_
6	included	include	VBD	_	4	relcl	_	_
7	187patients	0patients	NNS	_	6	obj	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	cases	case	NNS	_	7	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	and	and	CC	_	7	cc	_	_
14	189	0	CD	_	16	num	_	_
15	normal	normal	JJ	_	16	attr	_	_
16	subjects	subject	NNS	_	7	conj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	controls	control	NNS	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	,	,	,	_	34	p	_	_
21	the	the	DT	_	23	det	_	_
22	AA	aa	NN	_	23	com	_	_
23	genotype	genotype	NN	_	34	dep	_	_
24	and	and	CC	_	23	cc	_	_
25	variant	variant	JJ	_	28	attr	_	_
26	Met	met	NN	_	28	com	_	_
27	allele	allele	NN	_	28	com	_	_
28	frequencies	frequency	NNS	_	23	conj	_	_
29	of	of	IN	_	30	case	_	_
30	drug1	drug0	NN	_	23	ppmod	_	_
31	in	in	IN	_	33	case	_	_
32	the	the	DT	_	33	det	_	_
33	COMTgene	comtgene	NN	_	23	ppmod	_	_
34	were	be	VBD	_	0	root	_	_
35	significantly	significantly	RB	_	36	adv	_	_
36	higher	high	JJR	_	34	dep	_	_
37	in	in	IN	_	38	case	_	_
38	patients	patient	NNS	_	36	ppmod	_	_
39	with	with	IN	_	40	case	_	_
40	drug3	drug0	NN	_	38	ppmod	_	_
41	than	than	IN	_	42	case	_	_
42	those	those	DT	_	36	ppmod	_	_
43	in	in	IN	_	46	case	_	_
44	the	the	DT	_	46	det	_	_
45	control	control	NN	_	46	com	_	_
46	group	group	NN	_	42	ppmod	_	_
47	(	-lrb-	-LRB-	_	50	p	_	_
48	both	both	DT	_	50	det	_	_
49	p	p	NN	_	50	com	_	_
50	<0.05	<0	NN	_	46	prn	_	_
51	)	-rrb-	-RRB-	_	50	p	_	_
52	.	.	.	_	34	p	_	_

1	Compared	compare	VBN	_	3	adv	_	_
2	with	with	IN	_	3	case	_	_
3	nonsmokers	nonsmoker	NNS	_	12	ppmod	_	_
4	,	,	,	_	12	p	_	_
5	European-American	european-american	NN	_	9	attr	_	_
6	COMT	comt	NN	_	9	attr	_	_
7	drug1	drug0	NN	_	9	attr	_	_
8	double-variant	double-variant	JJ	_	9	attr	_	_
9	carriers	carrier	NNS	_	12	dep	_	_
10	who	who	WP	_	11	dep	_	_
11	smoked	smoke	VBD	_	9	relcl	_	_
12	had	have	VBD	_	0	root	_	_
13	increased	increase	VBN	_	14	attr	_	_
14	odds	odds	NNS	_	12	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	-LSB-adjusted	-lsb-adjusted	JJ	_	19	attr	_	_
18	odds	odds	NNS	_	19	com	_	_
19	ratio	ratio	NN	_	14	appo	_	_
20	(	-lrb-	-LRB-	_	30	p	_	_
21	AOR	aor	NN	_	30	dep	_	_
22	)	-rrb-	-RRB-	_	30	p	_	_
23	6.15	0	CD	_	30	num	_	_
24	,	,	,	_	30	p	_	_
25	95	0	CD	_	30	num	_	_
26	%	%	NN	_	30	meta	_	_
27	confidence	confidence	NN	_	30	attr	_	_
28	interval	interval	NN	_	30	attr	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	CI	ci	NN	_	19	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	1.32-28.78	0	CD	_	30	num	_	_
33	)	-rrb-	-RRB-	_	30	p	_	_
34	]	-rsb-	-RRB-	_	30	p	_	_
35	;	;	:	_	12	p	_	_

1	European-American	european-american	NN	_	5	attr	_	_
2	COMT	comt	NN	_	5	attr	_	_
3	drug1	drug0	NN	_	5	attr	_	_
4	double-variant	double-variant	JJ	_	5	attr	_	_
5	carriers	carrier	NNS	_	9	dep	_	_
6	who	who	WP	_	7	dep	_	_
7	smoked	smoke	VBD	_	5	relcl	_	_
8	heavily	heavily	RB	_	7	adv	_	_
9	had	have	VBD	_	0	root	_	_
10	more	more	RBR	_	11	adv	_	_
11	frequent	frequent	JJ	_	12	adv	_	_
12	moderate	moderate	JJ	_	15	attr	_	_
13	or	or	CC	_	12	cc	_	_
14	severe	severe	JJ	_	12	conj	_	_
15	drug2	drug0	NN	_	9	obj	_	_
16	than	than	IN	_	17	case	_	_
17	nonsmokers	nonsmoker	NNS	_	9	ppmod	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	AOR	aor	NN	_	17	prn	_	_
20	13.7	0	CD	_	19	num	_	_
21	,	,	,	_	19	p	_	_
22	95	0	CD	_	24	num	_	_
23	%	%	NN	_	22	meta	_	_
24	CI	ci	JJ	_	19	advcl	_	_
25	1.2-154.9	0	CD	_	24	obj	_	_
26	)	-rrb-	-RRB-	_	19	p	_	_
27	.	.	.	_	9	p	_	_

1	European-American	european-american	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	double-variant	double-variant	JJ	_	0	root	_	_
4	carriers	carrier	NNS	_	3	obj	_	_
5	who	who	WP	_	7	dep	_	_
6	smoked	smoke	VBD	_	7	aux	_	_
7	described	describe	VBD	_	4	relcl	_	_
8	more	more	RBR	_	9	adv	_	_
9	frequent	frequent	JJ	_	13	attr	_	_
10	moderate	moderate	JJ	_	13	attr	_	_
11	or	or	CC	_	10	cc	_	_
12	severe	severe	JJ	_	10	conj	_	_
13	drug2	drug0	NNS	_	7	obj	_	_
14	than	than	IN	_	36	case	_	_
15	nonsmoking	nonsmoking	JJ	_	36	attr	_	_
16	(	-lrb-	-LRB-	_	20	p	_	_
17	AOR	aor	NN	_	20	dep	_	_
18	20.6	0	CD	_	17	num	_	_
19	,	,	,	_	20	p	_	_
20	95	0	CD	_	15	num	_	_
21	%	%	NN	_	20	meta	_	_
22	CI	ci	JJR	_	20	attr	_	_
23	1.64-257.93	0	CD	_	22	num	_	_
24	)	-rrb-	-RRB-	_	20	p	_	_
25	and	and	CC	_	15	cc	_	_
26	never-smoking	never-smoking	JJ	_	15	conj	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	AOR	aor	NN	_	26	prn	_	_
29	20.59	0	CD	_	28	num	_	_
30	,	,	,	_	28	p	_	_
31	95	0	CD	_	33	num	_	_
32	%	%	NN	_	31	meta	_	_
33	CI	ci	JJ	_	28	advcl	_	_
34	1.39-304.68	0	CD	_	33	obj	_	_
35	)	-rrb-	-RRB-	_	28	p	_	_
36	carriers	carrier	NNS	_	7	ppmod	_	_
37	,	,	,	_	3	p	_	_
38	respectively	respectively	RB	_	3	adv	_	_
39	.	.	.	_	3	p	_	_

1	African-American	african-american	JJ	_	4	attr	_	_
2	single-variant	single-variant	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	carriers	carrier	NNS	_	7	dep	_	_
5	who	who	WP	_	6	dep	_	_
6	smoked	smoke	VBD	_	4	relcl	_	_
7	were	be	VBD	_	0	root	_	_
8	more	more	RBR	_	9	adv	_	_
9	likely	likely	JJ	_	7	dep	_	_
10	to	to	TO	_	11	aux	_	_
11	report	report	VBP	_	7	comp	_	_
12	drug2	drug0	NN	_	11	obj	_	_
13	than	than	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	nonsmoking	nonsmoking	JJ	_	16	attr	_	_
16	carriers	carrier	NNS	_	11	ppmod	_	_
17	(	-lrb-	-LRB-	_	21	p	_	_
18	AOR	aor	NN	_	21	dep	_	_
19	6.16	0	CD	_	18	num	_	_
20	,	,	,	_	21	p	_	_
21	95	0	CD	_	16	num	_	_
22	%	%	NN	_	21	meta	_	_
23	CI	ci	JJR	_	21	attr	_	_
24	1.11-33.91	0	CD	_	23	num	_	_
25	)	-rrb-	-RRB-	_	21	p	_	_
26	.	.	.	_	7	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	aimed	aim	VBD	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	test	test	VB	_	3	comp	_	_
6	the	the	DT	_	7	det	_	_
7	association	association	NN	_	5	obj	_	_
8	between	between	IN	_	12	case	_	_
9	the	the	DT	_	11	det	_	_
10	Val158Met	val0met	NN	_	11	com	_	_
11	polymorphism	polymorphism	NN	_	12	com	_	_
12	drug1	drug0	NN	_	7	ppmod	_	_
13	of	of	IN	_	20	case	_	_
14	the	the	DT	_	20	det	_	_
15	catechol-O-methyl	catechol-o-methyl	JJ	_	20	attr	_	_
16	transferase	transferase	NN	_	20	com	_	_
17	gene	gene	NN	_	20	com	_	_
18	andanorexia	andanorexia	NN	_	20	com	_	_
19	nervosa	nervosa	NN	_	20	com	_	_
20	drug2	drug0	NN	_	12	ppmod	_	_
21	.	.	.	_	3	p	_	_

1	The	the	DT	_	4	det	_	_
2	present	present	JJ	_	4	attr	_	_
3	association	association	NN	_	4	com	_	_
4	studies	study	NNS	_	5	dep	_	_
5	found	find	VBD	_	0	root	_	_
6	no	no	DT	_	7	det	_	_
7	association	association	NN	_	5	obj	_	_
8	between	between	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug1	drug0	NN	_	9	conj	_	_
12	when	when	WRB	_	13	adv	_	_
13	testing	test	VBG	_	5	comp	_	_
14	the	the	DT	_	19	det	_	_
15	allelic	allelic	JJ	_	18	attr	_	_
16	contrast	contrast	NN	_	18	com	_	_
17	-LSB-Utrecht	-lsb-utrecht	NN	_	18	com	_	_
18	odds	odds	NNS	_	19	com	_	_
19	ratio	ratio	NN	_	13	obj	_	_
20	(	-lrb-	-LRB-	_	23	p	_	_
21	OR	or	CC	_	23	cc	_	_
22	)	-rrb-	-RRB-	_	23	p	_	_
23	=1.14	0	NN	_	19	num	_	_
24	,	,	,	_	23	p	_	_
25	P=0.14	p=0	NN	_	23	appo	_	_
26	;	;	:	_	23	p	_	_
27	Leiden	leiden	NNP	_	30	attr	_	_
28	OR=1.02	or=0	NNP	_	30	attr	_	_
29	,	,	,	_	30	p	_	_
30	P=0.85	p=0	NNP	_	23	appo	_	_
31	]	-rsb-	-RRB-	_	23	p	_	_
32	.	.	.	_	5	p	_	_

1	Meta-analytically	meta-analytically	JJ	_	3	attr	_	_
2	combined	combined	JJ	_	3	attr	_	_
3	evidence	evidence	NN	_	12	dep	_	_
4	from	from	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	present	present	JJ	_	7	attr	_	_
7	genotypings	genotyping	NNS	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	the	the	DT	_	11	det	_	_
10	literature	literature	NN	_	11	com	_	_
11	search	search	NN	_	7	conj	_	_
12	shows	show	VBZ	_	0	root	_	_
13	that	that	IN	_	17	mark	_	_
14	the	the	DT	_	16	det	_	_
15	effect	effect	NN	_	16	com	_	_
16	sizes	size	NNS	_	17	dep	_	_
17	are	be	VBP	_	12	advcl	_	_
18	homogeneous	homogeneous	JJ	_	17	dep	_	_
19	across	across	IN	_	20	case	_	_
20	studies	study	NNS	_	18	ppmod	_	_
21	and	and	CC	_	17	cc	_	_
22	that	that	IN	_	26	mark	_	_
23	drug1	drug0	NN	_	26	dep	_	_
24	is	be	VBZ	_	26	aux	_	_
25	not	not	RB	_	26	neg	_	_
26	associated	associate	VBN	_	17	conj	_	_
27	with	with	IN	_	28	case	_	_
28	drug2	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	12	p	_	_

1	the	the	DT	_	4	det	_	_
2	COMT	comt	NN	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	SNP	snp	NN	_	13	dep	_	_
5	that	that	WDT	_	6	dep	_	_
6	reduces	reduce	VBZ	_	4	relcl	_	_
7	enzyme	enzyme	NN	_	8	com	_	_
8	activity	activity	NN	_	6	obj	_	_
9	,	,	,	_	4	p	_	_
10	has	have	VBZ	_	13	aux	_	_
11	previously	previously	RB	_	13	adv	_	_
12	been	be	VBN	_	13	aux	_	_
13	linked	link	VBN	_	0	root	_	_
14	to	to	TO	_	15	aux	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	13	p	_	_

1	Although	although	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	SNP	snp	NN	_	5	dep	_	_
5	was	be	VBD	_	0	root	_	_
6	not	not	RB	_	5	neg	_	_
7	a	a	DT	_	9	det	_	_
8	risk	risk	NN	_	9	com	_	_
9	factor	factor	NN	_	5	obj	_	_
10	for	for	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	.	_	5	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	conclude	conclude	VBP	_	0	root	_	_
3	that	that	IN	_	9	mark	_	_
4	the	the	DT	_	8	det	_	_
5	functional	functional	JJ	_	8	attr	_	_
6	COMT	comt	NN	_	8	com	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	SNP	snp	NN	_	9	dep	_	_
9	contributes	contribute	VBZ	_	2	comp	_	_
10	to	to	TO	_	11	aux	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	drug4	drug0	NN	_	11	conj	_	_
16	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	authors	author	NNS	_	3	dep	_	_
3	examined	examine	VBD	_	0	root	_	_
4	relations	relation	NNS	_	3	obj	_	_
5	between	between	IN	_	7	case	_	_
6	reproductive	reproductive	JJ	_	7	attr	_	_
7	factors	factor	NNS	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	5	0	CD	_	13	num	_	_
10	estrogen	estrogen	NN	_	13	com	_	_
11	pathway	pathway	NN	_	13	com	_	_
12	gene	gene	NN	_	13	com	_	_
13	polymorphisms	polymorphism	NNS	_	7	conj	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	drug1	drug0	NN	_	13	prn	_	_
16	,	,	,	_	15	p	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug3	drug0	NN	_	15	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug4	drug0	NN	_	15	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	COMT	comt	NN	_	25	com	_	_
25	drug5	drug0	NN	_	15	conj	_	_
26	)	-rrb-	-RRB-	_	15	p	_	_
27	among	among	IN	_	33	case	_	_
28	702	0	CD	_	33	num	_	_
29	Singapore	singapore	NN	_	33	attr	_	_
30	Chinese	chinese	JJ	_	33	attr	_	_
31	female	female	JJ	_	33	attr	_	_
32	drug6	drug0	NN	_	33	com	_	_
33	cases	case	NNS	_	4	ppmod	_	_
34	and	and	CC	_	33	cc	_	_
35	1,578	0	NN	_	37	num	_	_
36	hospital	hospital	NN	_	37	com	_	_
37	controls	control	NNS	_	33	conj	_	_
38	,	,	,	_	33	p	_	_
39	of	of	IN	_	40	case	_	_
40	whom	whom	WP	_	54	ppmod	_	_
41	433	0	CD	_	42	num	_	_
42	cases	case	NNS	_	54	dep	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	61.7	0	CD	_	42	num	_	_
45	%	%	NN	_	44	meta	_	_
46	)	-rrb-	-RRB-	_	44	p	_	_
47	and	and	CC	_	42	cc	_	_
48	1,375	0	CD	_	49	num	_	_
49	controls	control	NNS	_	42	conj	_	_
50	(	-lrb-	-LRB-	_	51	p	_	_
51	87.1	0	CD	_	49	num	_	_
52	%	%	NN	_	51	meta	_	_
53	)	-rrb-	-RRB-	_	51	p	_	_
54	were	be	VBD	_	33	relcl	_	_
55	never	never	RB	_	54	neg	_	_
56	smokers	smoker	NNS	_	54	obj	_	_
57	.	.	.	_	3	p	_	_

1	The	the	DT	_	5	det	_	_
2	COMT	comt	NN	_	5	com	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	A	a	NN	_	5	com	_	_
5	allele	allele	NN	_	8	dep	_	_
6	was	be	VBD	_	8	aux	_	_
7	positively	positively	RB	_	8	adv	_	_
8	associated	associate	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	never	never	RB	_	13	neg	_	_
13	smokers	smoker	NNS	_	10	ppmod	_	_
14	(	-lrb-	-LRB-	_	30	p	_	_
15	for	for	IN	_	16	case	_	_
16	G/A	g/a	NN	_	30	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	A/A	a/a	NN	_	16	conj	_	_
19	vs.	vs.	CC	_	18	cc	_	_
20	G/G	g/g	NN	_	18	conj	_	_
21	,	,	,	_	30	p	_	_
22	OR	or	CC	_	30	cc	_	_
23	=	=	JJ	_	30	attr	_	_
24	1.46	0	CD	_	26	num	_	_
25	,	,	,	_	26	p	_	_
26	95	0	CD	_	30	num	_	_
27	%	%	NN	_	26	meta	_	_
28	CI	ci	CD	_	30	num	_	_
29	:	:	:	_	30	p	_	_
30	1.12	0	CD	_	13	num	_	_
31	,	,	,	_	30	p	_	_
32	1.90	0	CD	_	30	appo	_	_
33	)	-rrb-	-RRB-	_	30	p	_	_
34	but	but	CC	_	13	cc	_	_
35	not	not	RB	_	38	neg	_	_
36	in	in	IN	_	38	case	_	_
37	ever	ever	RB	_	38	adv	_	_
38	smokers	smoker	NNS	_	13	conj	_	_
39	.	.	.	_	8	p	_	_

1	Thus	thus	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	we	we	PRP	_	4	dep	_	_
4	hypothesized	hypothesize	VBD	_	0	root	_	_
5	that	that	IN	_	12	mark	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	1	0	LS	_	12	num	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	the	the	DT	_	11	det	_	_
10	COMT	comt	NN	_	11	com	_	_
11	gene	gene	NN	_	12	dep	_	_
12	contributes	contribute	VBZ	_	4	comp	_	_
13	to	to	TO	_	14	aux	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	12	cc	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	2	0	LS	_	32	num	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	a	a	DT	_	21	det	_	_
20	COMT	comt	NN	_	21	com	_	_
21	polymorphism	polymorphism	NN	_	32	dep	_	_
22	(	-lrb-	-LRB-	_	25	p	_	_
23	drug1	drug0	NN	_	25	dep	_	_
24	:	:	:	_	25	p	_	_
25	Val158Met	val0met	NN	_	21	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	causing	cause	VBG	_	21	acl	_	_
28	thermolability	thermolability	NN	_	27	obj	_	_
29	of	of	IN	_	31	case	_	_
30	enzymatic	enzymatic	JJ	_	31	attr	_	_
31	activity	activity	NN	_	28	ppmod	_	_
32	affects	affect	VBZ	_	12	conj	_	_
33	liver	liver	NN	_	34	com	_	_
34	enzymes	enzyme	NNS	_	32	obj	_	_
35	(	-lrb-	-LRB-	_	39	p	_	_
36	e.g.	e.g.	FW	_	39	adv	_	_
37	,	,	,	_	39	p	_	_
38	aspartate	aspartate	NN	_	39	com	_	_
39	aminotransferase	aminotransferase	NN	_	34	prn	_	_
40	(	-lrb-	-LRB-	_	41	p	_	_
41	AST	ast	NN	_	39	prn	_	_
42	)	-rrb-	-RRB-	_	41	p	_	_
43	,	,	,	_	39	p	_	_
44	alanine	alanine	NN	_	45	com	_	_
45	aminotransferase	aminotransferase	NN	_	39	conj	_	_
46	(	-lrb-	-LRB-	_	47	p	_	_
47	ALT	alt	NN	_	45	prn	_	_
48	)	-rrb-	-RRB-	_	47	p	_	_
49	and	and	CC	_	45	cc	_	_
50	gamma-glutamyl	gamma-glutamyl	JJ	_	51	attr	_	_
51	transpeptidase	transpeptidase	NN	_	39	conj	_	_
52	(	-lrb-	-LRB-	_	53	p	_	_
53	γ-GT	γ-gt	NN	_	51	prn	_	_
54	)	-rrb-	-RRB-	_	53	p	_	_
55	)	-rrb-	-RRB-	_	39	p	_	_
56	in	in	IN	_	57	case	_	_
57	serum	serum	NN	_	32	ppmod	_	_
58	.	.	.	_	4	p	_	_

1	Recently	recently	RB	_	3	adv	_	_
2	we	we	PRP	_	3	dep	_	_
3	identified	identify	VBD	_	0	root	_	_
4	two	#crd#	CD	_	5	num	_	_
5	SNPs	snp	NNS	_	3	obj	_	_
6	in	in	IN	_	7	case	_	_
7	COMT	comt	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	drug1	drug0	NN	_	5	prn	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	)	-rrb-	-RRB-	_	9	p	_	_
13	that	that	WDT	_	15	dep	_	_
14	are	be	VBP	_	15	aux	_	_
15	associated	associate	VBN	_	5	relcl	_	_
16	with	with	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	in	in	IN	_	21	case	_	_
19	an	an	DT	_	21	det	_	_
20	Australian	australian	NN	_	21	com	_	_
21	cohort	cohort	NN	_	17	ppmod	_	_
22	.	.	.	_	3	p	_	_

1	Individuals	individual	NNS	_	4	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug3	drug0	NN	_	1	ppmod	_	_
4	were	be	VBD	_	0	root	_	_
5	more	more	RBR	_	4	adv	_	_
6	than	than	IN	_	5	case	_	_
7	twice	twice	RB	_	8	com	_	_
8	as	as	RB	_	9	adv	_	_
9	likely	likely	JJ	_	4	dep	_	_
10	to	to	TO	_	11	aux	_	_
11	carry	carry	VBP	_	4	comp	_	_
12	the	the	DT	_	14	det	_	_
13	GG	gg	NN	_	14	com	_	_
14	genotype	genotype	NN	_	11	obj	_	_
15	compared	compare	VBN	_	19	adv	_	_
16	to	to	TO	_	19	aux	_	_
17	the	the	DT	_	19	det	_	_
18	AA	aa	NN	_	19	com	_	_
19	genotype	genotype	NN	_	14	ppmod	_	_
20	for	for	IN	_	23	case	_	_
21	both	both	CC	_	23	cc	_	_
22	the	the	DT	_	23	det	_	_
23	drug1	drug0	NN	_	14	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	drug2	drug0	NN	_	26	com	_	_
26	SNPs	snp	NNS	_	23	conj	_	_
27	.	.	.	_	4	p	_	_

1	Association	association	NN	_	18	dep	_	_
2	of	of	IN	_	4	case	_	_
3	both	both	CC	_	4	cc	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	8	com	_	_
7	withsubstance	withsubstance	NN	_	8	com	_	_
8	dependence	dependence	NN	_	4	conj	_	_
9	,	,	,	_	4	p	_	_
10	a	a	DT	_	12	det	_	_
11	common	common	JJ	_	12	attr	_	_
12	comorbidity	comorbidity	NN	_	4	appo	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	has	have	VBZ	_	18	aux	_	_
16	not	not	RB	_	18	neg	_	_
17	been	be	VBN	_	18	aux	_	_
18	investigated	investigate	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	The	the	DT	_	3	det	_	_
2	drug1	drug0	JJ	_	3	attr	_	_
3	SNP	snp	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	associated	associate	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	SNP	snp	NN	_	4	dep	_	_
4	showed	show	VBD	_	0	root	_	_
5	a	a	DT	_	7	det	_	_
6	weak	weak	JJ	_	7	attr	_	_
7	association	association	NN	_	4	obj	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	at	at	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	allele	allele	NN	_	13	com	_	_
13	level	level	NN	_	4	ppmod	_	_
14	that	that	WDT	_	17	dep	_	_
15	did	do	VBD	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	reach	reach	VB	_	13	relcl	_	_
18	significance	significance	NN	_	17	obj	_	_
19	at	at	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	genotype	genotype	NN	_	22	com	_	_
22	level	level	NN	_	17	ppmod	_	_
23	but	but	CC	_	4	cc	_	_
24	it	it	PRP	_	27	dep	_	_
25	was	be	VBD	_	27	aux	_	_
26	not	not	RB	_	27	neg	_	_
27	associated	associate	VBN	_	4	conj	_	_
28	with	with	IN	_	29	case	_	_
29	drug3	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	4	p	_	_

1	Analysis	analysis	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	haplotypes	haplotype	NNS	_	1	ppmod	_	_
5	also	also	RB	_	6	adv	_	_
6	revealed	reveal	VBD	_	0	root	_	_
7	association	association	NN	_	6	obj	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	with	with	IN	_	13	case	_	_
11	the	the	DT	_	12	det	_	_
12	G/Ghaplotype	g/ghaplotype	NN	_	13	dep	_	_
13	being	be	VBG	_	7	ppmod	_	_
14	almost	almost	RB	_	15	adv	_	_
15	1.5	0	CD	_	18	num	_	_
16	times	time	NNS	_	15	attr	_	_
17	more	more	RBR	_	18	adv	_	_
18	common	common	JJ	_	13	dep	_	_
19	in	in	IN	_	21	case	_	_
20	drug3	drug0	NN	_	21	com	_	_
21	cases	case	NNS	_	18	ppmod	_	_
22	.	.	.	_	6	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	possible	possible	JJ	_	2	dep	_	_
4	that	that	IN	_	14	mark	_	_
5	the	the	DT	_	7	det	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	SNP	snp	NN	_	14	dep	_	_
8	,	,	,	_	7	p	_	_
9	in	in	IN	_	10	case	_	_
10	combination	combination	NN	_	7	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	7	p	_	_
14	results	result	VBZ	_	2	comp	_	_
15	in	in	IN	_	19	case	_	_
16	a	a	DT	_	19	det	_	_
17	common	common	JJ	_	19	attr	_	_
18	molecular	molecular	JJ	_	19	attr	_	_
19	variant	variant	NN	_	14	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	COMT	comt	NN	_	19	ppmod	_	_
22	that	that	WDT	_	23	dep	_	_
23	contributes	contribute	VBZ	_	19	relcl	_	_
24	to	to	TO	_	25	aux	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	drug4	drug0	NN	_	28	com	_	_
28	susceptibility	susceptibility	NN	_	25	conj	_	_
29	.	.	.	_	2	p	_	_

1	However	however	RB	_	42	adv	_	_
2	,	,	,	_	42	p	_	_
3	when	when	WRB	_	7	adv	_	_
4	this	this	DT	_	5	det	_	_
5	relation	relation	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	assessed	assess	VBN	_	42	advcl	_	_
8	within	within	IN	_	9	case	_	_
9	strata	strata	NN	_	7	ppmod	_	_
10	based	base	VBN	_	9	acl	_	_
11	on	on	IN	_	13	case	_	_
12	estrogen-related	estrogen-related	JJ	_	13	attr	_	_
13	factors	factor	NNS	_	10	ppmod	_	_
14	,	,	,	_	42	p	_	_
15	a	a	DT	_	17	det	_	_
16	few	few	JJ	_	17	attr	_	_
17	SNPs	snps	NN	_	42	dep	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	HSD17B1	hsd0b0	NN	_	21	dep	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	drug1	drug0	NN	_	17	prn	_	_
22	,	,	,	_	21	p	_	_
23	drug2	drug0	NN	_	21	conj	_	_
24	and	and	CC	_	23	cc	_	_
25	drug3	drug0	NN	_	21	conj	_	_
26	)	-rrb-	-RRB-	_	21	p	_	_
27	,	,	,	_	17	p	_	_
28	COMT	comt	NN	_	17	conj	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	drug4	drug0	NN	_	28	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	,	,	,	_	28	p	_	_
33	UGT1A1	ugt0a0	NN	_	17	conj	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	drug5	drug0	NN	_	33	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	and	and	CC	_	33	cc	_	_
38	ESR1	esr0	NN	_	17	conj	_	_
39	(	-lrb-	-LRB-	_	40	p	_	_
40	drug6	drug0	NN	_	38	prn	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	seemed	seem	VBD	_	0	root	_	_
43	to	to	TO	_	44	aux	_	_
44	be	be	VB	_	42	comp	_	_
45	related	related	JJ	_	44	dep	_	_
46	to	to	TO	_	47	aux	_	_
47	drug7	drug0	NN	_	45	ppmod	_	_
48	in	in	IN	_	51	case	_	_
49	the	the	DT	_	51	det	_	_
50	same	same	JJ	_	51	attr	_	_
51	direction	direction	NN	_	47	ppmod	_	_
52	of	of	IN	_	54	case	_	_
53	their	their	PRP$	_	54	poss	_	_
54	associations	association	NNS	_	51	ppmod	_	_
55	with	with	IN	_	56	case	_	_
56	drug8	drug0	NN	_	54	ppmod	_	_
57	.	.	.	_	42	p	_	_

1	we	we	PRP	_	2	dep	_	_
2	examined	examine	VBD	_	0	root	_	_
3	variations	variation	NNS	_	2	obj	_	_
4	in	in	IN	_	9	case	_	_
5	maternal	maternal	JJ	_	9	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	fetal	fetal	JJ	_	5	conj	_	_
8	COMT	comt	NN	_	9	com	_	_
9	genes	gene	NNS	_	3	ppmod	_	_
10	and	and	CC	_	3	cc	_	_
11	their	their	PRP$	_	12	poss	_	_
12	association	association	NN	_	3	conj	_	_
13	with	with	IN	_	14	case	_	_
14	drug5	drug0	NN	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	term	term	NN	_	14	prn	_	_
17	vs	vs	CC	_	16	cc	_	_
18	preterm	preterm	JJ	_	19	attr	_	_
19	pregnancies	pregnancy	NNS	_	16	conj	_	_
20	)	-rrb-	-RRB-	_	16	p	_	_
21	using	use	VBG	_	2	comp	_	_
22	4	0	CD	_	24	num	_	_
23	functional	functional	JJ	_	24	attr	_	_
24	SNPs	snp	NNS	_	21	obj	_	_
25	:	:	:	_	24	p	_	_
26	drug1	drug0	NN	_	24	appo	_	_
27	,	,	,	_	26	p	_	_
28	drug2	drug0	NN	_	26	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug3	drug0	NN	_	26	conj	_	_
31	,	,	,	_	30	p	_	_
32	and	and	CC	_	30	cc	_	_
33	drug4	drug0	NN	_	26	conj	_	_
34	in	in	IN	_	36	case	_	_
35	both	both	CC	_	36	cc	_	_
36	AA	aa	NN	_	26	ppmod	_	_
37	and	and	CC	_	36	cc	_	_
38	Cau	cau	NN	_	36	conj	_	_
39	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	conclusion	conclusion	NN	_	6	ppmod	_	_
3	,	,	,	_	6	p	_	_
4	our	our	PRP$	_	5	poss	_	_
5	study	study	NN	_	6	dep	_	_
6	demonstrated	demonstrate	VBD	_	0	root	_	_
7	that	that	IN	_	20	mark	_	_
8	a	a	DT	_	10	det	_	_
9	synonymous	synonymous	JJ	_	10	attr	_	_
10	polymorphism	polymorphism	NN	_	20	dep	_	_
11	,	,	,	_	10	p	_	_
12	drug1	drug0	NN	_	10	appo	_	_
13	in	in	IN	_	17	case	_	_
14	the	the	DT	_	17	det	_	_
15	fetal	fetal	JJ	_	17	attr	_	_
16	COMT	comt	NN	_	17	com	_	_
17	gene	gene	NN	_	12	ppmod	_	_
18	,	,	,	_	10	p	_	_
19	is	be	VBZ	_	20	aux	_	_
20	associated	associate	VBN	_	6	comp	_	_
21	with	with	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	in	in	IN	_	24	case	_	_
24	AA	aa	NN	_	22	ppmod	_	_
25	.	.	.	_	6	p	_	_

1	Variants	variant	NNS	_	9	dep	_	_
2	of	of	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	drug2	drug0	NN	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug3	drug0	NN	_	4	conj	_	_
7	were	be	VBD	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	associated	associate	VBN	_	0	root	_	_
10	with	with	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	risk	risk	NN	_	9	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	developing	develop	VBG	_	15	attr	_	_
15	drug4	drug0	NNS	_	12	ppmod	_	_
16	.	.	.	_	9	p	_	_

1	A	a	DT	_	4	det	_	_
2	common	common	JJ	_	4	attr	_	_
3	C-G-C-C-G-A	c-g-c-c-g-a	NN	_	4	com	_	_
4	haplotype	haplotype	NN	_	17	dep	_	_
5	for	for	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	-	-	:	_	6	p	_	_
8	drug2	drug0	NN	_	6	appo	_	_
9	-	-	:	_	6	p	_	_
10	drug3	drug0	NN	_	6	appo	_	_
11	-	-	:	_	6	p	_	_
12	drug4	drug0	NN	_	6	appo	_	_
13	-	-	:	_	6	p	_	_
14	drug5	drug0	NN	_	6	appo	_	_
15	-	-	:	_	6	p	_	_
16	drug6	drug0	NN	_	6	appo	_	_
17	showed	show	VBD	_	0	root	_	_
18	an	an	DT	_	20	det	_	_
19	inverse	inverse	JJ	_	20	attr	_	_
20	association	association	NN	_	17	obj	_	_
21	with	with	IN	_	23	case	_	_
22	drug7	drug0	NN	_	23	com	_	_
23	risk	risk	NN	_	20	ppmod	_	_
24	in	in	IN	_	26	case	_	_
25	Hispanic	hispanic	NNP	_	26	com	_	_
26	Caucasians	caucasians	NNP	_	17	ppmod	_	_
27	(	-lrb-	-LRB-	_	30	p	_	_
28	OR	or	CC	_	30	cc	_	_
29	=	=	JJ	_	30	attr	_	_
30	0.19	0	NN	_	26	num	_	_
31	,	,	,	_	30	p	_	_
32	P	p	NN	_	30	appo	_	_
33	=	=	JJ	_	32	attr	_	_
34	0.04	0	CD	_	36	num	_	_
35	,	,	,	_	36	p	_	_
36	95	0	CD	_	38	num	_	_
37	%	%	NN	_	36	meta	_	_
38	CI	ci	NN	_	33	advnp	_	_
39	=	=	JJ	_	38	attr	_	_
40	0.04-0.95	0	CD	_	39	num	_	_
41	)	-rrb-	-RRB-	_	30	p	_	_
42	and	and	CC	_	26	cc	_	_
43	with	with	IN	_	46	case	_	_
44	aggressive	aggressive	JJ	_	46	attr	_	_
45	disease	disease	NN	_	46	com	_	_
46	status	status	NN	_	56	ppmod	_	_
47	(	-lrb-	-LRB-	_	50	p	_	_
48	i.e.	i.e.	FW	_	50	ppmod	_	_
49	Gleason	gleason	NN	_	50	com	_	_
50	score	score	NN	_	46	prn	_	_
51	>or=7	>or=0	JJ	_	50	attr	_	_
52	)	-rrb-	-RRB-	_	50	p	_	_
53	in	in	IN	_	56	case	_	_
54	non-Hispanic	non-hispanic	JJ	_	56	attr	_	_
55	Caucasian	caucasian	NN	_	56	com	_	_
56	cases	case	NNS	_	26	conj	_	_
57	(	-lrb-	-LRB-	_	68	p	_	_
58	OR	or	CC	_	68	cc	_	_
59	=	=	JJ	_	68	attr	_	_
60	0.64	0	CD	_	63	num	_	_
61	,	,	,	_	63	p	_	_
62	P	p	NN	_	63	advnp	_	_
63	=	=	JJ	_	68	attr	_	_
64	0.008	0	CD	_	66	num	_	_
65	,	,	,	_	66	p	_	_
66	95	0	CD	_	63	num	_	_
67	%	%	NN	_	66	meta	_	_
68	CI	ci	NN	_	56	prn	_	_
69	=	=	JJ	_	68	attr	_	_
70	0.47-0.89	0	CD	_	68	num	_	_
71	)	-rrb-	-RRB-	_	68	p	_	_
72	.	.	.	_	17	p	_	_

1	A	a	DT	_	2	det	_	_
2	subset	subset	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	82	0	CD	_	5	num	_	_
5	patients	patient	NNS	_	2	ppmod	_	_
6	also	also	RB	_	7	adv	_	_
7	underwent	undergo	VBD	_	13	advcl	_	_
8	drug8	drug0	NN	_	9	com	_	_
9	testing	testing	NN	_	7	obj	_	_
10	,	,	,	_	13	p	_	_
11	Patients	patient	NNS	_	13	dep	_	_
12	were	be	VBD	_	13	aux	_	_
13	genotyped	genotyped	VBN	_	0	root	_	_
14	for	for	IN	_	19	case	_	_
15	the	the	DT	_	19	det	_	_
16	MTHFR	mthfr	NN	_	19	com	_	_
17	677C>T	0c>t	NN	_	19	com	_	_
18	drug1	drug0	NN	_	19	com	_	_
19	drug2	drug0	NN	_	13	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	MTR	mtr	NN	_	26	com	_	_
22	2756A>G	0a>g	NN	_	26	com	_	_
23	drug3	drug0	NN	_	26	com	_	_
24	MTRR	mtrr	NN	_	26	com	_	_
25	203A>G	0a>g	NN	_	26	com	_	_
26	drug4	drug0	NN	_	19	conj	_	_
27	,	,	,	_	26	p	_	_
28	FOLH1	folh0	NN	_	30	com	_	_
29	484T>C	0t>c	NN	_	30	com	_	_
30	drug5	drug0	NN	_	19	conj	_	_
31	,	,	,	_	30	p	_	_
32	RFC	rfc	NN	_	34	com	_	_
33	80A>G	0a>g	NN	_	34	com	_	_
34	drug6	drug0	NN	_	19	conj	_	_
35	and	and	CC	_	34	cc	_	_
36	COMT675G>A	comt0g>a	NN	_	38	com	_	_
37	drug7	drug0	NN	_	38	com	_	_
38	polymorphisms	polymorphism	NNS	_	19	conj	_	_
39	.	.	.	_	13	p	_	_

1	A	a	DT	_	4	det	_	_
2	common	common	JJ	_	4	attr	_	_
3	Val->Met	val->met	NN	_	4	com	_	_
4	polymorphism	polymorphism	NN	_	20	dep	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug1	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	in	in	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	COMT	comt	NN	_	11	com	_	_
11	gene	gene	NN	_	4	ppmod	_	_
12	,	,	,	_	4	p	_	_
13	associated	associate	VBN	_	4	acl	_	_
14	with	with	IN	_	18	case	_	_
15	increased	increase	VBN	_	18	attr	_	_
16	prefrontal	prefrontal	JJ	_	18	attr	_	_
17	dopamine	dopamine	NN	_	18	com	_	_
18	catabolism	catabolism	NN	_	13	ppmod	_	_
19	,	,	,	_	4	p	_	_
20	impairs	impair	VBZ	_	0	root	_	_
21	prefrontal	prefrontal	JJ	_	22	attr	_	_
22	cognition	cognition	NN	_	20	obj	_	_
23	and	and	CC	_	20	cc	_	_
24	might	might	MD	_	25	modal	_	_
25	increase	increase	VB	_	20	conj	_	_
26	risk	risk	NN	_	25	obj	_	_
27	for	for	IN	_	28	case	_	_
28	drug2	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	20	p	_	_

1	We	we	PRP	_	4	dep	_	_
2	have	have	VBP	_	4	aux	_	_
3	previously	previously	RB	_	4	adv	_	_
4	found	find	VBN	_	0	root	_	_
5	an	an	DT	_	6	det	_	_
6	association	association	NN	_	4	obj	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	addiction	addiction	NN	_	8	conj	_	_
12	.	.	.	_	4	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	12	mark	_	_
5	individual	individual	JJ	_	6	attr	_	_
6	susceptibility	susceptibility	NN	_	12	dep	_	_
7	to	to	TO	_	9	aux	_	_
8	drug4	drug0	NN	_	9	com	_	_
9	incidence	incidence	NN	_	6	ppmod	_	_
10	may	may	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	increased	increase	VBN	_	3	comp	_	_
13	by	by	IN	_	15	case	_	_
14	combined	combined	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	12	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	high-risk	high-risk	JJ	_	19	attr	_	_
19	genotypes	genotype	NNS	_	15	ppmod	_	_
20	in	in	IN	_	21	case	_	_
21	drug1	drug0	NN	_	15	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	drug2	drug0	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	drug3	drug0	NN	_	29	attr	_	_
27	estrogen	estrogen	NN	_	29	attr	_	_
28	metabolic	metabolic	JJ	_	29	attr	_	_
29	genes	gene	NNS	_	21	conj	_	_
30	.	.	.	_	3	p	_	_

1	The	the	DT	_	6	det	_	_
2	Val108/158Met	val0met	NN	_	6	attr	_	_
3	drug1	drug0	NN	_	6	attr	_	_
4	single	single	JJ	_	6	attr	_	_
5	nucleotide	nucleotide	NN	_	6	com	_	_
6	polymorphism	polymorphism	NN	_	17	dep	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	SNP	snp	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	in	in	IN	_	16	case	_	_
11	the	the	DT	_	16	det	_	_
12	catechol-O-methyltransferase	catechol-o-methyltransferase	NN	_	16	attr	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	COMT	comt	NN	_	16	attr	_	_
15	)	-rrb-	-RRB-	_	16	p	_	_
16	gene	gene	NN	_	6	ppmod	_	_
17	contributes	contribute	VBZ	_	0	root	_	_
18	to	to	TO	_	20	aux	_	_
19	genetic	genetic	JJ	_	20	attr	_	_
20	susceptibility	susceptibility	NN	_	17	ppmod	_	_
21	to	to	TO	_	22	aux	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	,	,	,	_	20	p	_	_
24	which	which	WDT	_	25	dep	_	_
25	is	be	VBZ	_	20	relcl	_	_
26	specifically	specifically	RB	_	25	adv	_	_
27	related	related	JJ	_	25	dep	_	_
28	to	to	TO	_	29	aux	_	_
29	impairments	impairment	NNS	_	27	ppmod	_	_
30	in	in	IN	_	31	case	_	_
31	executive	executive	NN	_	29	ppmod	_	_
32	functioning	function	VBG	_	31	acl	_	_
33	.	.	.	_	17	p	_	_

1	A	a	DT	_	4	det	_	_
2	different	different	JJ	_	4	attr	_	_
3	genomic	genomic	JJ	_	4	attr	_	_
4	region	region	NN	_	22	dep	_	_
5	composed	compose	VBN	_	4	acl	_	_
6	of	of	IN	_	8	case	_	_
7	three	#crd#	CD	_	8	num	_	_
8	SNPs	snp	NNS	_	5	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	drug1	drug0	NN	_	8	prn	_	_
11	,	,	,	_	10	p	_	_
12	drug2	drug0	NN	_	10	appo	_	_
13	,	,	,	_	10	p	_	_
14	drug3	drug0	NN	_	10	appo	_	_
15	)	-rrb-	-RRB-	_	10	p	_	_
16	within	within	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	COMT	comt	NN	_	19	com	_	_
19	gene	gene	NN	_	8	ppmod	_	_
20	has	have	VBZ	_	22	aux	_	_
21	been	be	VBN	_	22	aux	_	_
22	reported	report	VBN	_	0	root	_	_
23	to	to	TO	_	26	aux	_	_
24	be	be	VB	_	26	aux	_	_
25	significantly	significantly	RB	_	26	adv	_	_
26	associated	associate	VBN	_	22	comp	_	_
27	with	with	IN	_	28	case	_	_
28	drug4	drug0	NN	_	26	ppmod	_	_
29	in	in	IN	_	31	case	_	_
30	Ashkenazi	ashkenazi	JJ	_	31	attr	_	_
31	Jews	jew	NNS	_	28	ppmod	_	_
32	.	.	.	_	22	p	_	_

1	The	the	DT	_	3	det	_	_
2	SNP	snp	NN	_	3	com	_	_
3	drug1	drug0	NN	_	20	dep	_	_
4	,	,	,	_	3	p	_	_
5	which	which	WDT	_	8	dep	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	mapped	map	VBN	_	3	relcl	_	_
9	to	to	TO	_	12	aux	_	_
10	the	the	DT	_	12	det	_	_
11	3'-UTR	0'-utr	NN	_	12	com	_	_
12	region	region	NN	_	8	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	COMT	comt	NN	_	16	com	_	_
16	gene	gene	NN	_	12	ppmod	_	_
17	,	,	,	_	3	p	_	_
18	was	be	VBD	_	20	aux	_	_
19	significantly	significantly	RB	_	20	adv	_	_
20	associated	associate	VBN	_	0	root	_	_
21	with	with	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	in	in	IN	_	26	case	_	_
24	our	our	PRP$	_	26	poss	_	_
25	family	family	NN	_	26	com	_	_
26	study	study	NN	_	22	ppmod	_	_
27	,	,	,	_	20	p	_	_
28	and	and	CC	_	20	cc	_	_
29	possibly	possibly	RB	_	30	adv	_	_
30	associated	associate	VBN	_	20	conj	_	_
31	with	with	IN	_	33	case	_	_
32	the	the	DT	_	33	det	_	_
33	age	age	NN	_	30	ppmod	_	_
34	of	of	IN	_	35	case	_	_
35	onset	onset	NN	_	33	ppmod	_	_
36	,	,	,	_	35	p	_	_
37	delusion/hallucination	delusion/hallucination	NN	_	39	com	_	_
38	symptom	symptom	NN	_	39	com	_	_
39	dimension	dimension	NN	_	35	conj	_	_
40	,	,	,	_	39	p	_	_
41	and	and	CC	_	39	cc	_	_
42	CPT	cpt	NN	_	43	com	_	_
43	performance	performance	NN	_	35	conj	_	_
44	.	.	.	_	20	p	_	_

1	Therefore	therefore	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	COMT	comt	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	contribute	contribute	VB	_	0	root	_	_
6	to	to	TO	_	9	aux	_	_
7	the	the	DT	_	9	det	_	_
8	genetic	genetic	JJ	_	9	attr	_	_
9	risk	risk	NN	_	5	ppmod	_	_
10	for	for	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	not	not	RB	_	16	neg	_	_
13	through	through	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	polymorphism	polymorphism	NN	_	5	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	but	but	CC	_	16	cc	_	_
19	through	through	IN	_	21	case	_	_
20	other	other	JJ	_	21	attr	_	_
21	variants	variant	NNS	_	16	conj	_	_
22	that	that	WDT	_	24	dep	_	_
23	are	be	VBP	_	24	aux	_	_
24	situated	situated	JJ	_	21	relcl	_	_
25	3	0	CD	_	24	obj	_	_
26	'	'	''	_	25	p	_	_
27	to	to	TO	_	29	aux	_	_
28	this	this	DT	_	29	det	_	_
29	region	region	NN	_	24	ppmod	_	_
30	,	,	,	_	24	p	_	_
31	in	in	IN	_	34	case	_	_
32	the	the	DT	_	34	det	_	_
33	Taiwanese	taiwanese	NN	_	34	com	_	_
34	population	population	NN	_	24	ppmod	_	_
35	.	.	.	_	5	p	_	_

1	OBJECTIVE	objective	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	T	t	NN	_	5	com	_	_
5	allele	allele	NN	_	23	dep	_	_
6	of	of	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	functional	functional	JJ	_	9	attr	_	_
9	polymorphism	polymorphism	NN	_	5	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug1	drug0	NN	_	9	prn	_	_
12	:	:	:	_	11	p	_	_
13	LCT-13910	lct-0	CD	_	14	num	_	_
14	C>T	c>t	NN	_	11	appo	_	_
15	)	-rrb-	-RRB-	_	11	p	_	_
16	,	,	,	_	9	p	_	_
17	close	close	JJ	_	9	attr	_	_
18	to	to	TO	_	21	aux	_	_
19	the	the	DT	_	21	det	_	_
20	lactase	lactase	NN	_	21	com	_	_
21	gene	gene	NN	_	17	ppmod	_	_
22	,	,	,	_	9	p	_	_
23	correlates	correlate	VBZ	_	1	acl	_	_
24	with	with	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	LP	lp	NN	_	25	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	in	in	IN	_	30	case	_	_
30	adults	adult	NNS	_	25	ppmod	_	_
31	.	.	.	_	1	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	aim	aim	NN	_	3	dep	_	_
3	was	be	VBD	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	test	test	VB	_	3	comp	_	_
6	in	in	IN	_	8	case	_	_
7	this	this	DT	_	8	det	_	_
8	study	study	NN	_	5	ppmod	_	_
9	,	,	,	_	5	p	_	_
10	the	the	DT	_	11	det	_	_
11	association	association	NN	_	5	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	BMI	bmi	NN	_	11	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	related	related	JJ	_	18	attr	_	_
18	drug2	drug0	NN	_	15	conj	_	_
19	,	,	,	_	5	p	_	_
20	in	in	IN	_	21	case	_	_
21	interaction	interaction	NN	_	5	ppmod	_	_
22	with	with	IN	_	25	case	_	_
23	dairy	dairy	NN	_	25	com	_	_
24	product	product	NN	_	25	com	_	_
25	consumption	consumption	NN	_	21	ppmod	_	_
26	.	.	.	_	3	p	_	_

1	drug2	drug0	NN	_	6	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	PLI	pli	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	was	be	VBD	_	6	aux	_	_
6	defined	define	VBN	_	0	root	_	_
7	as	as	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	C/C	c/c	NN	_	10	com	_	_
10	genotype	genotype	NN	_	6	ppmod	_	_
11	of	of	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	polymorphism	polymorphism	NN	_	10	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	hypothesized	hypothesize	VBD	_	0	root	_	_
3	that	that	IN	_	17	mark	_	_
4	individuals	individual	NNS	_	17	dep	_	_
5	with	with	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	allele	allele	NN	_	4	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	LCT	lct	JJ	_	12	attr	_	_
12	SNP	snp	NN	_	8	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug1	drug0	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	would	would	MD	_	17	modal	_	_
17	exhibit	exhibit	VB	_	2	advcl	_	_
18	a	a	DT	_	20	det	_	_
19	greater	great	JJR	_	20	attr	_	_
20	degree	degree	NN	_	17	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	17	cc	_	_
24	that	that	IN	_	29	mark	_	_
25	this	this	DT	_	26	det	_	_
26	relationship	relationship	NN	_	29	dep	_	_
27	would	would	MD	_	29	modal	_	_
28	be	be	VB	_	29	aux	_	_
29	mediated	mediate	VBN	_	17	conj	_	_
30	by	by	IN	_	32	case	_	_
31	lactose	lactose	NN	_	32	com	_	_
32	consumption	consumption	NN	_	29	ppmod	_	_
33	.	.	.	_	2	p	_	_

1	The	the	DT	_	3	det	_	_
2	C/T-13910	c/t-0	NN	_	3	com	_	_
3	lactasevariant	lactasevariant	NN	_	8	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug1	drug0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	was	be	VBD	_	8	aux	_	_
8	genotyped	genotyped	VBN	_	0	root	_	_
9	in	in	IN	_	11	case	_	_
10	630	0	CD	_	11	num	_	_
11	men	man	NNS	_	8	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	11	cc	_	_
15	873	0	CD	_	18	num	_	_
16	matched	matched	JJ	_	18	attr	_	_
17	control	control	NN	_	18	com	_	_
18	participants	participant	NNS	_	11	conj	_	_
19	.	.	.	_	8	p	_	_

1	The	the	DT	_	3	det	_	_
2	-13910C>T	0c>t	NN	_	3	com	_	_
3	polymorphism	polymorphism	NN	_	27	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug1	drug0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	upstream	upstream	JJ	_	3	adv	_	_
8	from	from	IN	_	14	case	_	_
9	the	the	DT	_	14	det	_	_
10	lactase	lactase	NN	_	14	attr	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	LCT	lct	NN	_	14	attr	_	_
13	)	-rrb-	-RRB-	_	14	p	_	_
14	gene	gene	NN	_	7	ppmod	_	_
15	,	,	,	_	3	p	_	_
16	strongly	strongly	RB	_	17	adv	_	_
17	associated	associate	VBN	_	3	acl	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	LP	lp	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	in	in	FW	_	24	adv	_	_
24	Europeans	europeans	FW	_	17	adv	_	_
25	,	,	,	_	3	p	_	_
26	is	be	VBZ	_	27	aux	_	_
27	emerging	emerge	VBG	_	0	root	_	_
28	as	as	IN	_	31	case	_	_
29	a	a	DT	_	31	det	_	_
30	new	new	JJ	_	31	attr	_	_
31	candidate	candidate	NN	_	27	ppmod	_	_
32	for	for	IN	_	33	case	_	_
33	drug3	drug0	NN	_	31	ppmod	_	_
34	.	.	.	_	27	p	_	_

1	In	in	IN	_	2	case	_	_
2	contrast	contrast	NN	_	8	ppmod	_	_
3	,	,	,	_	8	p	_	_
4	haplotypes	haplotype	NNS	_	8	dep	_	_
5	at	at	IN	_	6	case	_	_
6	another	another	DT	_	4	ppmod	_	_
7	block	block	VBP	_	8	aux	_	_
8	tagged	tag	VBN	_	0	root	_	_
9	by	by	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	associated	associate	VBN	_	10	acl	_	_
12	with	with	IN	_	14	case	_	_
13	prevalent	prevalent	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	b=0.239	b=0	CD	_	14	num	_	_
17	,	,	,	_	16	p	_	_
18	p=	p=	NN	_	20	attr	_	_
19	2.05	0	CD	_	20	num	_	_
20	*	*	NN	_	16	appo	_	_
21	10	0	CD	_	20	num	_	_
22	(	-lrb-	-LRB-	_	20	p	_	_
23	-4	0	CD	_	20	num	_	_
24	)	-rrb-	-RRB-	_	20	p	_	_
25	)	-rrb-	-RRB-	_	16	p	_	_
26	,	,	,	_	8	p	_	_
27	but	but	CC	_	8	cc	_	_
28	remarkably	remarkably	RB	_	32	adv	_	_
29	these	these	DT	_	32	dep	_	_
30	are	be	VBP	_	32	aux	_	_
31	inversely	inversely	RB	_	32	adv	_	_
32	associated	associate	VBN	_	8	conj	_	_
33	with	with	IN	_	35	case	_	_
34	disease	disease	NN	_	35	com	_	_
35	severity	severity	NN	_	32	ppmod	_	_
36	(	-lrb-	-LRB-	_	39	p	_	_
37	b=-0.196	b=-0	CD	_	39	num	_	_
38	,	,	,	_	39	p	_	_
39	p=0.003	p=0	CD	_	32	num	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	presence	presence	NN	_	20	dep	_	_
3	of	of	IN	_	9	case	_	_
4	four	#crd#	CD	_	9	num	_	_
5	common	common	JJ	_	9	attr	_	_
6	oxytocin	oxytocin	NN	_	9	com	_	_
7	receptor	receptor	NN	_	9	com	_	_
8	gene	gene	NN	_	9	com	_	_
9	polymorphisms	polymorphism	NNS	_	2	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug1	drug0	NN	_	9	prn	_	_
12	,	,	,	_	11	p	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	11	conj	_	_
16	and	and	CC	_	15	cc	_	_
17	drug4	drug0	NN	_	11	conj	_	_
18	)	-rrb-	-RRB-	_	11	p	_	_
19	was	be	VBD	_	20	aux	_	_
20	evaluated	evaluate	VBN	_	0	root	_	_
21	in	in	IN	_	24	case	_	_
22	one	#crd#	CD	_	23	com	_	_
23	hundred	#crd#	CD	_	24	num	_	_
24	women	woman	NNS	_	20	ppmod	_	_
25	with	with	IN	_	26	case	_	_
26	drug5	drug0	NN	_	24	ppmod	_	_
27	and	and	CC	_	24	cc	_	_
28	one	#crd#	CD	_	29	com	_	_
29	hundred	#crd#	CD	_	31	num	_	_
30	healthy	healthy	JJ	_	31	attr	_	_
31	women	woman	NNS	_	24	conj	_	_
32	using	use	VBG	_	31	acl	_	_
33	restriction	restriction	NN	_	36	com	_	_
34	fragment	fragment	NN	_	36	com	_	_
35	length	length	NN	_	36	com	_	_
36	polymorphism	polymorphism	NN	_	32	obj	_	_
37	genotyping	genotyping	VBG	_	36	acl	_	_
38	.	.	.	_	20	p	_	_

1	In	in	IN	_	3	case	_	_
2	haplotype	haplotype	NN	_	3	com	_	_
3	analysis	analysis	NN	_	21	ppmod	_	_
4	,	,	,	_	21	p	_	_
5	the	the	DT	_	7	det	_	_
6	haplotype	haplotype	NN	_	7	com	_	_
7	combination	combination	NN	_	21	dep	_	_
8	of	of	IN	_	11	case	_	_
9	drug1	drug0	NN	_	11	com	_	_
10	A	a	NN	_	11	com	_	_
11	allele	allele	NN	_	7	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug2	drug0	NN	_	15	com	_	_
14	C	c	NN	_	15	com	_	_
15	allele	allele	NN	_	11	conj	_	_
16	and	and	CC	_	15	cc	_	_
17	drug3	drug0	NN	_	19	com	_	_
18	G	g	NN	_	19	com	_	_
19	allele	allele	NN	_	11	conj	_	_
20	was	be	VBD	_	21	aux	_	_
21	found	find	VBN	_	0	root	_	_
22	to	to	TO	_	25	aux	_	_
23	be	be	VB	_	25	aux	_	_
24	significantly	significantly	RB	_	25	adv	_	_
25	associated	associate	VBN	_	21	comp	_	_
26	with	with	IN	_	29	case	_	_
27	an	an	DT	_	29	det	_	_
28	increased	increase	VBN	_	29	attr	_	_
29	risk	risk	NN	_	25	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	drug4	drug0	NN	_	29	ppmod	_	_
32	(	-lrb-	-LRB-	_	38	p	_	_
33	OR=3.2	or=0	CD	_	34	num	_	_
34	-LSB-CI	-lsb-ci	NN	_	38	dep	_	_
35	1.04-9.8	0	CD	_	34	num	_	_
36	]	-rsb-	-RRB-	_	34	p	_	_
37	,	,	,	_	38	p	_	_
38	p=0.043	p=0	CD	_	25	num	_	_
39	)	-rrb-	-RRB-	_	38	p	_	_
40	.	.	.	_	21	p	_	_

1	With	with	IN	_	5	case	_	_
2	respect	respect	NN	_	5	advnp	_	_
3	to	to	TO	_	5	aux	_	_
4	OXTR	oxtr	NN	_	5	com	_	_
5	drug1	drug0	NN	_	12	ppmod	_	_
6	,	,	,	_	12	p	_	_
7	mothers	mother	NNS	_	12	dep	_	_
8	with	with	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	GG	gg	NN	_	11	com	_	_
11	genotype	genotype	NN	_	7	ppmod	_	_
12	showed	show	VBD	_	0	root	_	_
13	greater	great	JJR	_	14	attr	_	_
14	drug2	drug0	NN	_	12	obj	_	_
15	across	across	IN	_	17	case	_	_
16	varying	varying	JJ	_	17	attr	_	_
17	levels	level	NNS	_	12	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	interparental	interparental	JJ	_	20	attr	_	_
20	conflict	conflict	NN	_	17	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	aim	aim	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	study	study	NN	_	2	ppmod	_	_
6	was	be	VBD	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	investigate	investigate	VB	_	6	comp	_	_
9	whether	whether	IN	_	40	mark	_	_
10	a	a	DT	_	11	det	_	_
11	set	set	NN	_	40	dep	_	_
12	of	of	IN	_	15	case	_	_
13	single	single	JJ	_	15	attr	_	_
14	nucleotide	nucleotide	NN	_	15	com	_	_
15	polymorphisms	polymorphism	NNS	_	11	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	SNPs	snp	NNS	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	within	within	IN	_	38	case	_	_
20	cyclooxygenase-2	cyclooxygenase-0	NN	_	38	attr	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	COX-2	cox-0	NN	_	20	prn	_	_
23	,	,	,	_	22	p	_	_
24	drug1	drug0	NN	_	22	conj	_	_
25	and	and	CC	_	24	cc	_	_
26	drug2	drug0	NN	_	22	conj	_	_
27	)	-rrb-	-RRB-	_	22	p	_	_
28	and	and	CC	_	20	cc	_	_
29	oxytocin	oxytocin	NN	_	30	com	_	_
30	receptor	receptor	NN	_	20	conj	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	OXTR	oxtr	NN	_	30	prn	_	_
33	,	,	,	_	32	p	_	_
34	drug3	drug0	NN	_	32	conj	_	_
35	and	and	CC	_	34	cc	_	_
36	drug4	drug0	NN	_	32	conj	_	_
37	)	-rrb-	-RRB-	_	32	p	_	_
38	genes	gene	NNS	_	15	ppmod	_	_
39	was	be	VBD	_	40	aux	_	_
40	associated	associate	VBN	_	8	comp	_	_
41	with	with	IN	_	42	case	_	_
42	drug5	drug0	NN	_	40	ppmod	_	_
43	,	,	,	_	42	p	_	_
44	response	response	NN	_	42	conj	_	_
45	or	or	CC	_	44	cc	_	_
46	remission	remission	NN	_	42	conj	_	_
47	.	.	.	_	6	p	_	_

1	For	for	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	purpose	purpose	NN	_	33	ppmod	_	_
4	,	,	,	_	33	p	_	_
5	two	#crd#	CD	_	8	num	_	_
6	single	single	JJ	_	8	attr	_	_
7	nucleotide	nucleotide	NN	_	8	com	_	_
8	polymorphisms	polymorphism	NNS	_	33	dep	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	SNPs	snp	NNS	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	,	,	,	_	8	p	_	_
13	6930G>A	0g>a	NN	_	8	appo	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	drug1	drug0	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	and	and	CC	_	13	cc	_	_
18	9073G>A	0g>a	NN	_	13	conj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	drug2	drug0	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	,	,	,	_	8	p	_	_
23	within	within	IN	_	27	case	_	_
24	the	the	DT	_	27	det	_	_
25	oxytocin	oxytocin	NN	_	27	com	_	_
26	receptor	receptor	NN	_	27	com	_	_
27	gene	gene	NN	_	8	ppmod	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	OXTR	oxtr	NN	_	27	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	,	,	,	_	8	p	_	_
32	were	be	VBD	_	33	aux	_	_
33	studied	study	VBN	_	0	root	_	_
34	in	in	IN	_	36	case	_	_
35	a	a	DT	_	36	det	_	_
36	cohort	cohort	NN	_	33	ppmod	_	_
37	of	of	IN	_	39	case	_	_
38	185	0	CD	_	39	num	_	_
39	patients	patient	NNS	_	36	ppmod	_	_
40	with	with	IN	_	42	case	_	_
41	major	major	JJ	_	42	attr	_	_
42	drug3	drug0	NN	_	39	ppmod	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	50.3	0	CD	_	42	num	_	_
45	%	%	NN	_	44	meta	_	_
46	)	-rrb-	-RRB-	_	44	p	_	_
47	or	or	CC	_	42	cc	_	_
48	drug4	drug0	NN	_	42	conj	_	_
49	I	i	CD	_	48	num	_	_
50	or	or	CC	_	48	cc	_	_
51	II	ii	CD	_	52	num	_	_
52	disorders	disorder	NNS	_	48	conj	_	_
53	(	-lrb-	-LRB-	_	54	p	_	_
54	49.7	0	CD	_	39	num	_	_
55	%	%	NN	_	54	meta	_	_
56	)	-rrb-	-RRB-	_	54	p	_	_
57	and	and	CC	_	39	cc	_	_
58	192	0	CD	_	61	num	_	_
59	matched	match	VBN	_	61	attr	_	_
60	healthy	healthy	JJ	_	61	attr	_	_
61	controls	control	NNS	_	39	conj	_	_
62	.	.	.	_	33	p	_	_

1	A	a	DT	_	3	det	_	_
2	positive	positive	JJ	_	3	attr	_	_
3	association	association	NN	_	20	dep	_	_
4	between	between	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	GG	gg	NN	_	7	com	_	_
7	genotype	genotype	NN	_	3	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	SNPs	snps	NN	_	3	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	6930G>A	0g>a	NN	_	10	prn	_	_
13	or	or	CC	_	12	cc	_	_
14	9073G>A	0g>a	NN	_	12	conj	_	_
15	)	-rrb-	-RRB-	_	12	p	_	_
16	and	and	CC	_	10	cc	_	_
17	unipolar	unipolar	NN	_	18	com	_	_
18	drug2	drug0	NN	_	10	conj	_	_
19	was	be	VBD	_	20	aux	_	_
20	demonstrated	demonstrate	VBN	_	0	root	_	_
21	.	.	.	_	20	p	_	_

1	For	for	IN	_	2	case	_	_
2	drug1	drug0	NN	_	15	ppmod	_	_
3	,	,	,	_	15	p	_	_
4	overtransmission	overtransmission	NN	_	15	dep	_	_
5	of	of	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	G	g	NN	_	8	com	_	_
8	allele	allele	NN	_	4	ppmod	_	_
9	to	to	TO	_	10	aux	_	_
10	probands	proband	NNS	_	4	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	disorder	disorder	NN	_	10	ppmod	_	_
14	was	be	VBD	_	15	aux	_	_
15	found	find	VBN	_	0	root	_	_
16	which	which	WDT	_	17	dep	_	_
17	contrasts	contrast	VBZ	_	15	comp	_	_
18	with	with	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	overtransmission	overtransmission	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	A	a	DT	_	20	ppmod	_	_
23	previously	previously	RB	_	24	adv	_	_
24	reported	report	VBN	_	22	acl	_	_
25	in	in	IN	_	29	case	_	_
26	the	the	DT	_	29	det	_	_
27	Chinese	chinese	NN	_	29	com	_	_
28	Han	han	NN	_	29	com	_	_
29	sample	sample	NN	_	24	ppmod	_	_
30	.	.	.	_	15	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	6	det	_	_
4	family-based	family-based	JJ	_	6	attr	_	_
5	association	association	NN	_	6	com	_	_
6	test	test	NN	_	10	dep	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	FBAT	fbat	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	revealed	reveal	VBD	_	1	acl	_	_
11	a	a	DT	_	14	det	_	_
12	significant	significant	JJ	_	14	attr	_	_
13	genetic	genetic	JJ	_	14	attr	_	_
14	association	association	NN	_	10	obj	_	_
15	between	between	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	two	#crd#	CD	_	16	conj	_	_
19	of	of	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	SNPs	snp	NNS	_	18	ppmod	_	_
22	tested	test	VBN	_	21	acl	_	_
23	(	-lrb-	-LRB-	_	42	p	_	_
24	drug1	drug0	NN	_	25	com	_	_
25	A	a	NN	_	42	dep	_	_
26	:	:	:	_	42	p	_	_
27	Z	z	NN	_	28	advnp	_	_
28	=	=	JJ	_	29	attr	_	_
29	2.287	0	CD	_	42	num	_	_
30	,	,	,	_	42	p	_	_
31	p	p	NN	_	42	dep	_	_
32	=	=	JJ	_	31	attr	_	_
33	.0222	0	CD	_	36	num	_	_
34	;	;	:	_	36	p	_	_
35	drug2	drug0	CD	_	36	num	_	_
36	A	a	NN	_	32	advnp	_	_
37	:	:	:	_	42	p	_	_
38	Z	z	NN	_	39	advnp	_	_
39	=	=	JJ	_	40	attr	_	_
40	2.573	0	CD	_	42	num	_	_
41	,	,	,	_	42	p	_	_
42	p	p	NN	_	18	prn	_	_
43	=	=	JJ	_	42	attr	_	_
44	.0101	0	CD	_	42	num	_	_
45	)	-rrb-	-RRB-	_	42	p	_	_
46	.	.	.	_	1	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	haplotypes	haplotype	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	constructed	construct	VBN	_	17	advcl	_	_
5	with	with	IN	_	12	case	_	_
6	two	#crd#	CD	_	12	num	_	_
7	,	,	,	_	6	p	_	_
8	three	#crd#	CD	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	four	#crd#	CD	_	6	conj	_	_
12	markers	marker	NNS	_	4	ppmod	_	_
13	,	,	,	_	17	p	_	_
14	the	the	DT	_	16	det	_	_
15	haplotype-specific	haplotype-specific	JJ	_	16	attr	_	_
16	FBAT	fbat	NN	_	17	dep	_	_
17	revealed	reveal	VBD	_	0	root	_	_
18	that	that	IN	_	31	mark	_	_
19	a	a	DT	_	20	det	_	_
20	number	number	NN	_	31	dep	_	_
21	of	of	IN	_	22	case	_	_
22	haplotypes	haplotype	NNS	_	20	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	particularly	particularly	RB	_	25	adv	_	_
25	those	those	DT	_	22	appo	_	_
26	involving	involve	VBG	_	25	acl	_	_
27	drug1	drug0	NN	_	26	obj	_	_
28	,	,	,	_	22	p	_	_
29	were	be	VBD	_	31	aux	_	_
30	significantly	significantly	RB	_	31	adv	_	_
31	associated	associate	VBN	_	17	comp	_	_
32	with	with	IN	_	33	case	_	_
33	drug2	drug0	NN	_	31	ppmod	_	_
34	.	.	.	_	17	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Our	our	PRP$	_	4	poss	_	_
4	meta-analysis	meta-analysis	NN	_	5	dep	_	_
5	suggests	suggest	VBZ	_	1	acl	_	_
6	that	that	IN	_	14	mark	_	_
7	the	the	DT	_	9	det	_	_
8	G	g	NN	_	9	com	_	_
9	allele	allele	NN	_	14	dep	_	_
10	of	of	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	polymorphism	polymorphism	NN	_	9	ppmod	_	_
13	might	might	MD	_	14	modal	_	_
14	be	be	VB	_	5	comp	_	_
15	a	a	DT	_	18	det	_	_
16	potential	potential	JJ	_	18	attr	_	_
17	risk	risk	NN	_	18	com	_	_
18	factor	factor	NN	_	14	obj	_	_
19	for	for	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	,	,	,	_	14	p	_	_
22	especially	especially	RB	_	24	adv	_	_
23	in	in	IN	_	24	case	_	_
24	whitepopulations	whitepopulations	NN	_	14	ppmod	_	_
25	.	.	.	_	1	p	_	_

1	The	the	DT	_	5	det	_	_
2	real-time	real-time	JJ	_	5	attr	_	_
3	polymerase	polymerase	NN	_	5	com	_	_
4	chain	chain	NN	_	5	com	_	_
5	reaction	reaction	NN	_	10	dep	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	RT-PCR	rt-pcr	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	was	be	VBD	_	10	aux	_	_
10	used	use	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	analyze	analyze	VB	_	10	comp	_	_
13	4	0	CD	_	14	num	_	_
14	SNPs	snp	NNS	_	12	obj	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	A/G	a/g	NN	_	14	prn	_	_
18	,	,	,	_	17	p	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	A/G	a/g	NN	_	17	appo	_	_
21	,	,	,	_	17	p	_	_
22	drug3	drug0	NN	_	23	com	_	_
23	A/G	a/g	NN	_	17	appo	_	_
24	,	,	,	_	17	p	_	_
25	drug4	drug0	NN	_	26	com	_	_
26	C/G	c/g	NN	_	17	appo	_	_
27	)	-rrb-	-RRB-	_	17	p	_	_
28	in	in	IN	_	31	case	_	_
29	291	0	CD	_	31	num	_	_
30	drug5	drug0	NN	_	31	com	_	_
31	patients	patient	NNS	_	14	ppmod	_	_
32	and	and	CC	_	31	cc	_	_
33	247	0	CD	_	34	num	_	_
34	controls	control	NNS	_	31	conj	_	_
35	.	.	.	_	10	p	_	_

1	Analysis	analysis	NN	_	5	dep	_	_
2	of	of	IN	_	4	case	_	_
3	4	0	CD	_	4	num	_	_
4	SNPs	snp	NNS	_	1	ppmod	_	_
5	revealed	reveal	VBD	_	0	root	_	_
6	a	a	DT	_	8	det	_	_
7	significant	significant	JJ	_	8	attr	_	_
8	difference	difference	NN	_	5	obj	_	_
9	in	in	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	genotype	genotype	NN	_	12	com	_	_
12	distribution	distribution	NN	_	8	ppmod	_	_
13	for	for	IN	_	14	case	_	_
14	drug1	drug0	NN	_	8	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	drug3	drug0	NN	_	14	conj	_	_
20	between	between	IN	_	22	case	_	_
21	drug5	drug0	NN	_	22	com	_	_
22	patients	patient	NNS	_	14	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	controls	control	NNS	_	22	conj	_	_
25	(	-lrb-	-LRB-	_	30	p	_	_
26	p	p	NN	_	28	attr	_	_
27	=	=	JJ	_	28	attr	_	_
28	0.041	0	NN	_	30	num	_	_
29	,	,	,	_	30	p	_	_
30	p	p	NN	_	24	prn	_	_
31	=	=	JJ	_	30	attr	_	_
32	0.005	0	CD	_	30	num	_	_
33	,	,	,	_	30	p	_	_
34	p	p	NN	_	35	dep	_	_
35	=	=	JJ	_	30	advcl	_	_
36	0.023	0	CD	_	35	obj	_	_
37	,	,	,	_	35	p	_	_
38	respectively	respectively	RB	_	35	adv	_	_
39	)	-rrb-	-RRB-	_	30	p	_	_
40	but	but	CC	_	14	cc	_	_
41	not	not	RB	_	43	neg	_	_
42	for	for	IN	_	43	case	_	_
43	drug4	drug0	NN	_	14	conj	_	_
44	(	-lrb-	-LRB-	_	45	p	_	_
45	p	p	NN	_	43	prn	_	_
46	=	=	JJ	_	45	attr	_	_
47	0.211	0	CD	_	45	num	_	_
48	)	-rrb-	-RRB-	_	45	p	_	_
49	.	.	.	_	5	p	_	_

1	Minor	minor	JJ	_	2	attr	_	_
2	alleles	allele	NNS	_	24	dep	_	_
3	in	in	IN	_	7	case	_	_
4	three	#crd#	CD	_	7	num	_	_
5	correlated	correlated	JJ	_	7	attr	_	_
6	ht	ht	NN	_	7	com	_	_
7	SNPs	snp	NNS	_	2	ppmod	_	_
8	(	-lrb-	-LRB-	_	17	p	_	_
9	drug1	drug0	NN	_	17	dep	_	_
10	,	,	,	_	17	p	_	_
11	,	,	,	_	12	p	_	_
12	drug2	drug0	NN	_	17	dep	_	_
13	,	,	,	_	12	p	_	_
14	and	and	CC	_	12	cc	_	_
15	drug3	drug0	NN	_	12	conj	_	_
16	;	;	:	_	17	p	_	_
17	r	r	NN	_	7	prn	_	_
18	(	-lrb-	-LRB-	_	17	p	_	_
19	2	0	CD	_	17	num	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	>0.6	>0	CD	_	17	num	_	_
22	)	-rrb-	-RRB-	_	17	p	_	_
23	were	be	VBD	_	24	aux	_	_
24	associated	associate	VBN	_	0	root	_	_
25	with	with	IN	_	27	case	_	_
26	increased	increase	VBN	_	27	attr	_	_
27	risk	risk	NN	_	24	ppmod	_	_
28	for	for	IN	_	29	case	_	_
29	drug4	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	24	p	_	_

